A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.
The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
Deoxyribonucleic acid that makes up the genetic material of viruses.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host.
INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.
Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P=O)O2 structure.
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
A purine base and a fundamental unit of ADENINE NUCLEOTIDES.
INFLAMMATION of the LIVER in humans caused by a member of the HEPATOVIRUS genus, HUMAN HEPATITIS A VIRUS. It can be transmitted through fecal contamination of food or water.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding.
Substances that are recognized by the immune system and induce an immune reaction.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
Tumors or cancer of the LIVER.
INFLAMMATION of the LIVER.
The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION.
Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed)
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.
A DNA virus that closely resembles human hepatitis B virus. It has been recovered from naturally infected ducks.
Any of the viruses that cause inflammation of the liver. They include both DNA and RNA viruses as well viruses from humans and animals.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Proteins prepared by recombinant DNA technology.
Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
Substances elaborated by bacteria that have antigenic activity.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A country spanning from central Asia to the Pacific Ocean.
Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Therapy with two or more separate preparations given for a combined effect.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
INFLAMMATION of the LIVER in animals due to viral infection.
INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
Substances elaborated by viruses that have antigenic activity.
Elements of limited time intervals, contributing to particular results or situations.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis B and chronic hepatitis. It requires the presence of a hepadnavirus for full replication. This is the lone species in the genus Deltavirus.
Acute INFLAMMATION of the LIVER in humans; caused by HEPATITIS E VIRUS, a non-enveloped single-stranded RNA virus. Similar to HEPATITIS A, its incubation period is 15-60 days and is enterically transmitted, usually by fecal-oral transmission.
Antibodies to the HEPATITIS A ANTIGENS including antibodies to envelope, core, and non-structural proteins.
A positive-stranded RNA virus species in the genus HEPEVIRUS, causing enterically-transmitted non-A, non-B hepatitis (HEPATITIS E).
A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES.
EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A strain of HEPATITIS A VIRUS which causes hepatitis in humans. The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the fecal-oral route.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
Ribonucleic acid that makes up the genetic material of viruses.
INFLAMMATION of the LIVER in non-human animals.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID.
An ORTHOHEPADNAVIRUS causing chronic liver disease and hepatocellular carcinoma in woodchucks. It closely resembles the human hepatitis B virus.
Antigens produced by various strains of HEPATITIS D VIRUS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Antigens of the virions of HEPACIVIRUS, their surface, core, or other associated antigens.

Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. (1/743)

Virus load and liver damage, as measured by quantitative polymerase chain reaction and histology activity index, were related to genotype and core promoter mutations in 43 chronic hepatitis B virus (HBV) carriers of East Asian origin. T-1762 mutants were more frequent in genotype C strains and were associated with more inflammation (P=.0036) and fibrosis (P=.0088) of the liver but not with hepatitis B e antigen (HBeAg) status or virus load. Conversely, precore mutations were associated with less liver inflammation (P=. 08), which was linked to HBeAg negativity and lower viral replication. Carriers with genotype C were more often HBeAg positive (P=.03) with precore wild type strains and more-severe liver inflammation (P=.009) than were those with genotype B. These findings suggest that pathogenic differences between genotypes may exist and that the T-1762 mutation may be useful as a marker for progressive liver damage but seem to contradict that down-regulation of HBeAg production is the major effect of this mutation.  (+info)

Hepatitis B vaccination in high-risk infants: 10-year follow-up. (2/743)

The long-term efficacy of hepatitis B vaccination among high-risk infants was determined in 805 vaccine responders, immunized at birth in Taiwan during 1981-1984 and followed to age 10 years, via life table survival and Cox multivariate analyses. At 10 years, cumulative persistence of antibody to hepatitis B surface antigen (anti-HBs) was 85%, and cumulative incidence of hepatitis B virus (HBV) infection was 15%. Three children became carriers. Twelve-month anti-HBs titer was the strongest predictor of efficacy. The higher the initial titer, the lower the risk of anti-HBs loss (relative risk [RR], 0.26 for titer of 100-999 mIU/mL; RR, 0.08 for titer >1000 mIU/mL; P<.001) and HBV infection (RR, 0.55 and 0.27; P<.05). Maternal hepatitis B e antigen positivity but not hepatitis B immunoglobulin dose or gender predicted greater antibody persistence to age 10 years. Because the level of antibody persistence remained high and few became carriers, booster revaccination within 10 years seems unnecessary.  (+info)

Quantitative analysis of hepatitis B virus precore mutant in hepatitis type B. (3/743)

Active liver disease has been detected in chronic hepatitis B after seroconversion from positive HBe antigen to positive anti-HBe antibody. Active replication of HB virus (HBV) containing a precore stop-codon mutation has been implicated in this condition. The usual methods, such as direct sequencing, to characterize the responsible mutant of HBV are not suitable for routine clinical use. Here we employed the competitive mutation site specific assay (CMSSA) to detect precore mutant HBV-DNA in patients with positive HB surface antigen. In patients with HBe antigen, precore mutant HBV-DNA was significantly higher than in patients with HBe antibody. The level of precore mutant HBV-DNA in patients with elevated serum ALT was significantly higher than in patients with normal serum ALT. Sex, age and the level of serum HBV-associated DNA polymerase levels were not correlated with levels of precore mutant HBV-DNA. Ten of 11 negative patients for the precore mutant by polymerase chain reaction followed by restriction fragment length polymorphism assay (PCRRFLP) were positive for the precore mutant by CMSSA. These results suggest that the precore mutant has already emerged in the HBeAg-positive phase as determined by CMSSA, which is more sensitive than PCR-RFLP and is useful for evaluating the clinical course of patients with chronic hepatitis B.  (+info)

Hepatitis B surface antigen disappearance and hepatitis B surface antigen subtype: a prospective, long-term, follow-up study of Japanese residents of Okinawa, Japan with chronic hepatitis B virus infection. (4/743)

To determine the natural course of hepatitis B surface antigen (HBsAg) disappearance in chronic hepatitis B virus (HBV) infection and the factors related to its disappearance, 946 HBsAg carriers in Okinawa, Japan were prospectively followed for up to 19 years (mean = 9.2 years). The disappearance of HBsAg, as determined by radioimmunoassay (RIA), was observed in 62 (6.6%) and the overall annual disappearance rate was 0.79%/year. Its disappearance was more frequent in 60 (7.4%) of 815 serum samples negative for hepatitis B e antigen (HBeAg) by RIA at entry compared with only two (1.5%) of 131 serum samples that were HBeAg positive by RIA at entry (P < 0.05). Stepwise logistic regression analysis showed that age and HBsAg subtype were significantly associated with HBsAg disappearance (both P < 0.05), and that carriers with subtype adr (odds ratio = 2.87) had an increased probability of clearing HBsAg compared with carriers with subtype adw. Conversely, HBeAg disappearance was earlier in those with the adw subtype than in those with adr. Hepatitis B virus DNA was not detected by the polymerase chain reaction after HBsAg disappearance in any of the 62 from whom it had disappeared. The HBsAg titer, as measured by reverse passive hemagglutination, was related to the time to its disappearance; the higher the titer, the longer the time to disappearance. These findings suggest that HBeAg negativity, a more advanced age, and low titers of HBsAg are favorable factors for HBsAg disappearance in the natural course of chronic HBV infection. Moreover, HBsAg subtype adr was a predictive factor for HBsAg disappearance, whereas subtype adw was predictive of early HBeAg disappearance.  (+info)

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. (5/743)

In a pilot study, it was established that specific therapy by standard anti-hepatitis B virus (HBV) vaccination may be effective in reducing HBV replication and canceling the immune tolerance to hepatitis B surface antigen (HBsAg) particles in about 50% of persons with chronic active HBV replication. In the present study, the vaccine-induced immune responses were analyzed during an ongoing controlled multicenter vaccine trial. Vaccination elicited peripheral blood mononuclear cell proliferative responses specific for envelope antigen in 7 of 27 subjects given HBsAg. The responses induced by the vaccines were mediated by CD4+ T lymphocytes, and at least three different epitopes were recognized. HBV-specific CD4+ T lymphocytes produced high levels of interferon-gamma [corrected] and belonged to a T helper 1 subset. Reduction of serum HBV DNA in some of these persons suggests that induction of CD4+ T cell responses could be important in controlling viremia during vaccine therapy of chronic HBV carriers.  (+info)

Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. (6/743)

A combinatorial screening method has been used to identify hairpin ribozymes that inhibit hepatitis B virus (HBV) replication in transfected human hepatocellular carcinoma (HCC) cells. A hairpin ribozyme library (5 x 10(5) variants) containing a randomized substrate-binding domain was used to identify accessible target sites within 3.3 kb of full-length in vitro-transcribed HBV pregenomic RNA. Forty potential target sites were found within the HBV pregenomic RNA, and 17 sites conserved in all four subtypes of HBV were chosen for intracellular inhibition experiments. Polymerase II and III promoter expression constructs for corresponding hairpin ribozymes were generated and cotransfected into HCC cells together with a replication-competent dimer of HBV DNA. Four ribozymes inhibited HBV replication by 80, 69, 66, and 49%, respectively, while catalytically inactive mutant forms of these ribozymes affected HBV replication by 36, 28, 0, and 0%. These findings indicate that the inhibitory effects on HBV replication were largely mediated by the catalytic activity of the ribozymes. In conclusion, we have identified catalytically active RNAs by combinatorial screening that mediate intracellular antiviral effects on HBV.  (+info)

Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-1 infections in selected Solomon Islands populations. (7/743)

To determine the prevalences of hepatitis B virus (HBV), hepatitis C virus (HCV), and human T lymphotropic virus type-1 (HTLV-1) infections in residents of the Solomon Islands, we surveyed 1,610 serum samples from 1,113 outpatients and 497 healthy volunteer blood donors at the Central Hospital in Honiara, the Solomon Islands. The prevalence of hepatitis B surface antigen (HBsAg) by radioimmunoassay (RIA) (n = 315, 19.6%) was significantly different from that of antibody to HCV (anti-HCV) by a second-generation enzyme immunoassay (EIA) (n = 4, 0.2%) and antibody to HTLV-1 (anti-HTLV-1) by an ELISA with Western blot analysis to verify the positivity (n = 49, 3.0%) (P < 0.0001, respectively). There were no significant differences in the prevalences of these markers between outpatients and blood donors. Hepatitis B e antigen (HBeAg) was detected by RIA in 130 (41.3%) of 315 HBsAg-positive samples. The distribution of HBsAg subtypes by EIA was 190 adr (60.3%), 111 ayw (35.2%), and 14 (0.4%) other subtypes. The HBeAg prevalence decreased with age in all groups for each subtype. There were no significant differences in the prevalence of HBeAg among HBsAg subtypes. We conclude that HBV infection is highly endemic in selected Solomon Islands populations, and that the high prevalence of HBeAg may be associated with the spread of HBV infection there.  (+info)

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. (8/743)

The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2x/day) or lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day) to zidovudine-containing background antiretroviral treatment. Baseline hepatitis B surface antigen (HBsAg) results were available for 1790 study subjects, of whom 122 (6.8%) tested positive. Retrospective analyses for serial HBV DNA, HBsAg, and hepatitis B e antigen (HBeAg) were performed on stored sera from 118 HBsAg-positive subjects. HBV DNA and HBeAg were present in 83% and 63%, respectively. At weeks 12 and 52, median log10 HBV DNA change was -2.0 and -2.7, respectively, in the lamivudine arms, compared with no reduction among placebo recipients (P<.001). A trend to lower alanine transferase level, and delayed progression of HIV-1 disease (relative hazard, 0.26; 95% confidence interval, 0.08-0.80) were also seen in the lamivudine arms, compared with the placebo group.  (+info)

We read with great interest the recent chronic hepatitis B (CHB) (AASLD) practice guideline written eminently by 2 of the most experienced hepatologists in CHB.1 Hepatitis B e antigen (HBeAg)-negative CHB is characterized by increased levels of alanine aminotransferase (ALT)/ aspartate aminotransferase (AST), serum hepatitis B virus (HBV)-DNA , 2,000 IU/mL, and moderate/severe necroinflammation, whereas the inactive hepatitis B surface antigen (HBsAg) carrier state is defined as persistently normal ALT/AST on ≥3-4 determinations made every 3 months (then every 6-12 months) and HBV-DNA , 2,000 IU/mL.1. According to our unpublished, recent, prospective cohort of 150 HBeAg-negative chronic HBV patients with a close biochemical and virological follow-up, a substantial proportion (22% of cases or 28% of 228 serum samples tested) of 85 patients with persistently normal ALT/AST levels have HBV-DNA , 2,000 IU/mL (15% at 2,000-5,000 IU/mL and 7% at 5,000-20,000 IU/mL). Such patients are excluded from ...
Buy our Recombinant Hepatitis B Virus E Antigen protein. Ab91273 is an active full length protein produced in Escherichia coli and has been validated in WB…
BioAssay record AID 378283 submitted by ChEMBL: Inhibition of Hepatitis B virus E antigen activity in human MS-G2 cells at 10 ug/mL.
TY - JOUR. T1 - Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients. T2 - A long term cohort study. AU - Brunetto, Maurizia Rossana. AU - Oliveri, Filippo. AU - Coco, Barbara. AU - Leandro, Gioacchino. AU - Colombatto, Piero. AU - Gorin, Juliana Monti. AU - Bonino, Ferruccio. PY - 2002. Y1 - 2002. N2 - Background/Aims: We studied the influence of biochemical and virologic patterns and interferon on the outcome of anti-HBe positive chronic hepatitis B in 164 (103 treated) consecutive patients, followed-up prospectively for a mean of 6 years (21 months-12 years). Methods: Histology, biochemical and virologic profiles were characterized by monthly monitoring during the first 12 months of follow-up. Thereafter patients underwent blood and clinical controls every 4 and 6 months, respectively. Cirrhosis at follow-up histology or end stage complications of cirrhosis served as end points for the analysis of factors influencing disease progression in ...
TY - JOUR. T1 - Retroviral-mediated transfer and expression of hepatitis B e antigen in human primary skin fibroblasts and Esptein-Barr virus-transformed B lymphocytes. AU - Raney, A. K.. AU - Milich, D. R.. AU - Hughes, J. L.. AU - Sorge, J.. AU - Chisari, F. V.. AU - Mondelli, M. U.. AU - McLachlan, A.. PY - 1989. Y1 - 1989. N2 - Previously, an amphotropic retroviral expression system coding for the neomycin resistance gene was developed and used to synthesize hepatitis B e antigen (HBeAg) and hepatitis B core/e antigen (HBc/eAg) in transfected mouse NIH 3T3 fibroblasts (A. McLachlan et al., 1987, J. Virol. 61, 683-692). In the present study, these transfected cell lines were infected with a helper amphotropic murine leukemia virus resulting in the production of infectious recombinant retrovirus. The recombinant retrovirus was examined for its capacity to transmit resistance to the antibiotic, G418, and to express hepatitis B virus antigens in mouse NIH 3T3 fibroblasts, human primary skin ...
The underlying mechanisms for earlier hepatitis B e antigen (HBeAg) seroconversion in patients with chronic hepatitis B virus (HBV) genotype B when compared with genotype C are unknown. We aimed to determine whether there were any differences in the T helper (Th) responses during hepatitis flares in HBeAg-positive patients with genotypes B and C. Proliferative response measured by 3H-thymidine uptake and Th responses measured by Enzyme-Linked Immunosorbent Spot assays for interleukin (IL)-2, interferon-gamma (IFN-γ), IL-4, IL-5 and IL-10 were performed in 10 patients with genotype B and 10 with genotype C with hepatitis flares. HBV genotypes, core promoter, precore mutations, sequence of HBV core region and HBV DNA levels were determined. There was no difference in the HBV DNA levels during hepatitis flares between patients with genotypes B and C. Patients with genotype B had a significantly higher number of IFN-γ producing cells [with hepatitis B core antigen (HBcAg) stimulation] and lower ...
Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.. Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug.. ...
Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.. Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug.. ...
Hepatitis b e antigen definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it up now!
Tseng, T.-C., Liu, C.-J., Yang, H.-C., Su, T.-H., Wang, C.-C., Chen, C.-L., Fang-Tzu Kuo, S., Liu, C.-H., Chen, P.-J., Chen, D.-S. and Kao, J.-H. (2012), Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology, 55: 68-76. doi: 10.1002/hep.24615 ...
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of NTU Repository with Academic Hub to form NTU Scholars.. ...
Background & Aims: A previous 4-week trial of telbivudine in patients with chronic hepatitis B indicated marked antiviral effects with good tolerability, leading to the present 1-year phase 2b trial. Methods: This randomized, double-blind, multicenter trial evaluated the efficacy and safety of telbivudine 400 or 600 mg/day and telbivudine 400 or 600 mg/day plus lamivudine 100 mg/day (Comb400 and Comb600) compared with lamivudine 100 mg/day in hepatitis B e antigen (HBeAg)-positive adults with compensated chronic hepatitis B. Results: A total of 104 patients were randomized 1:1:1:1:1 among the 5 groups. Median reductions in serum hepatitis B virus (HBV) DNA levels at week 52 (log 10 copies/mL) were as follows: lamivudine, 4.66; telbivudine 400 mg, 6.43; telbivudine 600 mg, 6.09; Comb400, 6.40; and Comb600, 6.05. At week 52, telbivudine monotherapy showed a significantly greater mean reduction in HBV DNA levels (6.01 vs 4.57 log 10 copies/mL; P < .05), clearance of polymerase chain ...
Hepatitis B surface antigen, hepatitis B e antigen, hepatitis B virus DNA, alanine aminotransferase, liver histology, quantification
International Journal of Hepatology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the medical, surgical, pathological, biochemical, and physiological aspects of hepatology, as well as the management of disorders affecting the liver, gallbladder, biliary tree, and pancreas.
Mouse monoclonal antibody raised against recombinant hepatitis B virus e antigen. Recombinant protein corresponding to hepatitis B virus e antigen. (MAB0466) - Products - Abnova
Hepatitis B E Antigen (HBeAg) is a protein found in hepatitis B virus. It is tested in patients suspected of having active hepatitis B infection.
Result 184 patients (mean age 53.9 years, 67.9% male) were recruited. The cumulative rate of virologic relapse at 24 and 48 weeks was 74.2% and 91.4%, respectively. The median HBV DNA level at virologic relapse was 11 000 (range 2115 to ,1.98×108) IU/mL. 42 (25.8%) patients had elevated alanine aminotransferase (median level 97 U/L, range 37-1058 U/L) during virologic relapse. Mean rate of off-treatment HBsAg decline was 0.018 (±0.456) log IU/mL/year. No patients cleared HBsAg. There was no correlation between off-treatment serial HBsAg and HBV DNA levels (r=−0.026, p=0.541). HBsAg levels at the time of entecavir commencement, entecavir cessation and the subsequent rate of HBsAg reduction were not associated with virologic relapse (all p,0.05).. ...
Different guidelines exist for the management of hepatitis B virus (HBV)-infected healthcare workers (HCWs). Various HBV DNA levels are used as a cutoff level to determine whether an HBV-infected healthcare worker is allowed to perform exposure-prone procedures (EPPs) or not. OSAP member and Arthur A. Dugoni Pacific School of Dentistry faculty member, Eve Cuny MS, has done extensive research on this topic. The Board of OSAP thanks Ms. Cuny for her generosity in sharing articles, a sample policy and a copy of a presentation she made on this topic at the 2009 OSAP Annual Symposium.. If readers have additional materials they wish to contribute to this toolkit, please click HERE ...
Objective: To assess risk factors for liver-related death, we re-evaluated, after a median follow-up of 25 years, a cohort of 70 Caucasian patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis (CH) at presentation.. Methods: Follow-up studies included clinical and ultrasound examinations, biochemical and virological tests, and cause of death.. Results: Sixty-one (87%) patients underwent spontaneous HBeAg seroconversion. During a median period of 22.8 years after HBeAg seroclearance, 40 (66%) patients became inactive carriers, whereas the remaining 21 (34%) showed alanine aminotransferase elevation: one (1%) had HBeAg reversion, nine (15%) detectable serum HBV DNA but were negative for HBeAg, eight (13%) concurrent virus(es) infection and three (5%) concurrent non-alcoholic fatty liver disease. Liver-related death occurred in 11 (15.7%) patients, caused by hepatocellular carcinoma in five and liver failure in six. The 25-year survival probability was 40% in patients persistently ...
T cell proliferative responses to hepatitis B virus-encoded envelope antigen (S + preS2 + preS1), recombinant core antigen (HBcAg), and natural hepatitis B e antigen (HBeAg) were examined in 22 HBeAg-positive patients with chronic type B hepatitis and 17 healthy hepatitis B surface antigen (HBsAg) carriers. The results showed that HBeAg-positive patients had (a) higher levels of T cell responses to HBcAg/HBeAg than those of healthy HBsAg carriers (P less than 0.001 and P less than 0.01, respectively); (b) a further increase in these T cell responses during acute exacerbations (P less than 0.05 and P less than 0.05, respectively); (c) subsidence in the T cell responses to HBcAg/HBeAg after recovery from acute exacerbations and HBeAg seroconversion, whereas the responses would persist at high levels if the patients did not enter a clinical remission; and (d) low levels of T cell responses to S + preS2 + preS1 either before or after HBeAg seroconversion. The appearance of increasing T cell ...
When a patient with hepatitis B e antigen positive infection undergoes treatment, we like to see the patient lose their e antigen and gain e antibody. That tells us the patient has \
High baseline serum levels of interleukin (IL)-23 can help to identify hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who are likely to respond to pegylated interferon (PegIFN) treatment, a Chinese study indicates. Baseline serum levels of the cytokines … Continue reading →. ...
Hepatitis B virus (HBV), a small and economically packaged double-stranded DNA virus, represents an enormous global health care burden. In spite of an effective vaccine, HBV is endemic in many countries. Chronic hepatitis B (CHB) results in the development of significant clinical outcomes such as liver disease and hepatocellular carcinoma (HCC), which are associated with high mortality rates. HBV is a non-cytopathic virus, with the hosts immune response responsible for the associated liver damage. Indeed, HBV appears to be a master of manipulating and modulating the immune response to achieve persistent and chronic infection. The HBV precore protein or hepatitis B e antigen (HBeAg) is a key viral protein involved in these processes, for instance though the down-regulation of the innate immune response. The development of new therapies that target viral proteins, such as HBeAg, which regulates of the immune system, may offer a new wave of potential therapeutics to circumvent progression to CHB ...
Objective To examine viral evolutionary changes and their relationship to hepatitis B e antigen (HBeAg) seroconversion. Design A matched case-control study of HBeAg seroconverters (n=8) and non-seroconverters (n=7) with adequate stored sera before seroconversion was performed. Nested PCR, cloning and sequencing of hepatitis B virus (HBV) precore/core gene was performed. Sequences were aligned using Clustal X2.0, followed by construction of phylogenetic trees using Pebble 1.0. Viral diversity, evolutionary rates and positive selection were then analysed. Results Baseline HBV quasispecies viral diversity was identical in seroconverters and non-seroconverters 10 years before seroconversion but started to increase approximately 3 years later. Concurrently, precore stop codon (PSC) mutations appeared. Some 2 years later, HBV-DNA declined, together with a dramatic reduction in HBeAg titres. Just before HBeAg seroconversion, seroconverters had HBV-DNA levels 2 log lower (p=0.008), HBeAg titres 310-fold smaller
The long-term goal of chronic hepatitis B (CHB) treatment is improvement of liver disease and prevention of cirrhosis. The aim of this study was to assess whether prolonged telbivudine treatment improves liver inflammation and fibrosis. The primary objective was to evaluate the proportion of patients with absence/minimal inflammation (Knodell necroinflammatory score a parts per thousand currency sign3) on liver biopsy at Year 5.. Fifty-seven patients aged 16-70 years with a clinical history of CHB and active viral replication (38 hepatitis B e antigen [HBeAg] positive and 19 HBeAg negative) were followed for 6 years: 33 received telbivudine 600 mg/day continuously for 5 years; 24 received lamivudine 100 mg/day for 2 years and then telbivudine for 3 years. Liver biopsies were taken pre-treatment and after 5 years of treatment.. At baseline, mean (standard deviation) serum hepatitis B virus (HBV) DNA load was 8.5 (1.7) log(10) copies/mL, Knodell necroinflammatory score was 7.6 (2.9), and Ishak ...
Factors that Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa Erik. H.C.J. Buster, Bettina E. Hansen, George K.K. Lau , Teerha Piratvisuth, Stefan Zeuzem, Ewout W. Steyerberg and Harry L.A. Janssen Gastroenterology 2009; 137(6): 2002-2009. ...
Our previous OSST study shows that switching to pegylated interferon (Peg-IFN)-α2a results in higher rates of response hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss at the end of treatment, compared with nucleot(s)ide analogues (NAs) monotherapy in long term NA-treated chronic hepatitis B (CHB) patients. In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study ...
Hepatitis B e (Envelop) Antigen (HbeAg): View interpretation of results, purpose, procedure, answers to patient concerns/FAQs and book at lowest prices from labs and diagnostic centers in your city on 1mg.com.
Book Hepatitis B e (Envelope) Antibody In New Delhi online from Prednalytics Laboratory. View test prices, normal range, sample results and user reviews about labs only on 1mg
The data reported to the FDA via FAERS frequently have many gaps, as demonstrated in this report. These data bear no resemblance to those of the clinical trials, and the FDA has a difficult job in determining whether a previously unrecognized safety event is occurring. In addition, much of the data clinicians require to understand an events effect on clinical management are unavailable. The HCV guidelines of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) now recommend that patients receive testing for HBsAg, HBsAb, and HBcAb before beginning HCV treatment (9). These guidelines recommend that patients who have positive results on HBsAg testing undergo a full evaluation of their HBV status (including hepatitis B e antigen status and HBV DNA levels). If a patient meets the criteria for HBV treatment, he or she should receive it before beginning HCV therapy. Otherwise, HBV DNA should be monitored during HCV treatment; if, while ...
In May 1995 a dentist practising in central Scotland was discovered to be hepatitis B e antigen seropositive and therefore highly infectious. The dentist ceased clinical practice immediately and an incident team was convened.. The 6,753 patients treated by the dentist during his professional career were identified and cross-matched with the records of notifications and laboratory diagnoses of hepatitis B since 1988. No patients were shown to have developed clinical hepatitis B subsequent to treatment by the dentist.. The incident group then debated whether there should be any further action. One view expressed was that since routine data sources had identified no clinical cases of hepatitis B amongst the dentists patients, the probability of undetected transmission was very low. A look back exercise notifying the dentists former patients would therefore cause them unnecessary anxiety with little health benefit. The contrasting view was that patients had the right to know that they had been ...
During Malaria Treatment I was tested for HbSAg and which was found reactive and hence we gone for HBeAg and ANTI HBcAg-IgM Which was found negative .. So what is its meaning and should I go for Vaccin...
This study is to evaluate the safety, tolerability, and efficacy of nivolumab treatment with or without GS-4774 in adults with HBeAg-negative chronic hepatitis
I would want to know what the HBV DNA result is -- if it is suppressed that would be great news. If so, I would check the HBe Antibody as well. If that is positive, then that would be additional...
A close friend was recently diagnosed as having Hep B. After a 2nd test the results have come back HBeag cutoff marker 1.00, score 0.157 - non reactive Anti HBeag cutoff marker 1.00, score 0.344 -...
I look like an adult. I feel like an adult. I certainly have the bills of an adult. But for some reason, my dad still thinks Im a child. What gives?
I s s u e 1 7 , O c t o b e r - D e c e m b e r 2 0 0 5 Goto www.wddty.com. And cal me for the info sheet I Hope you al had a beautiful summer; we have had a very busy summer and look forward to the winter, staying warm indoors and sharing with you al . We are in the process of setting up a formal complementary health practice at home. We wil be giving Jin Shin In the last newsletter I wr ...
A precore mutant is a variety of hepatitis B virus that does not produce hepatitis B virus e antigen (HBeAg). These mutants are important because infections caused by these viruses are difficult to treat, and can cause infections of prolonged duration and with a higher risk of liver cirrhosis. The mutations are changes in DNA bases from guanine to adenine at base position 1896 (G1896A), and from cytosine to thymine at position 1858 (C1858T) in the precore region of the viral genome. The HBV has four genes: S, P, C, and X. The S gene codes for the major envelope protein (HBsAg). The largest gene is P. It codes for DNA polymerase. The C gene codes for HBeAg and HBcAg. The C gene has a precore and a core region. If translation is initiated at the precore region, the protein product is HBeAg. If translation begins with the core region, HBcAg is the protein product. HBeAg is a marker of HBV replication and infectivity. The precore region is not necessary for viral replication. Precore mutants can ...
Definition of hepatitis B e antigen. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
This exploratory study investigated nivolumab with or without GS-4774 in patients with HBeAg negative chronic hepatitis B infection
Background & aims Virological breakthrough (VBT) could be a manifestation of chronic hepatitis B (CHB) in patients treated with long-term nucleot(s)ide analogues. We aimed to determine the association of on-treatment serum hepatitis B virus (HBV) DNA with VBT in HBeAg-positive CHB patients receiving entecavir (ETV) treatment. Methods A retrospective cohort study, including 162 consecutive patients (95 men and 67 women; mean age, 43.1±13.4 years) with HBeAg-positive CHB treated with ETV for at least 48 weeks between August 2008 and May 2015, was conducted. Univariate and multivariate cox regression analysis were used to identify associations with VBT and clinical factors, including HBV DNA and HBeAg serum status. Results Among the 162 ETV-treated HBeAg-positive CHB patients, eighteen patients (11.1%) experienced VBT (VBT group), whereas the other 144 patients were without VBT (non-VBT group). The cumulative rate of HBV DNA | 100 IU/mL in the VBT group and the non-VBT group at week 48 were 44.44% and
TY - JOUR. T1 - Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. AU - Byung, Chul Yoo. AU - Ju, Hyun Kim. AU - Chung, Young Hwa. AU - Kwan, Sik Lee. AU - Seung, Woon Paik. AU - Soo, Hyung Ryu. AU - Byung, Hoon Han. AU - Han, Joon Yeol. AU - Kwan, Soo Byun. AU - Cho, Mong. AU - Lee, Heon Ju. AU - Kim, Tae Hun. AU - Cho, Se Hyun. AU - Park, Joong Won. AU - Um, Soon Ho. AU - Seong, Gyu Hwang. AU - Young, Soo Kim. AU - Lee, Youn Jae. AU - Chae, Yoon Chon. AU - Kim, Byung Ik. AU - Lee, Young Suk. AU - Yang, Jin Mo. AU - Haak, Cheoul Kim. AU - Jae, Seok Hwang. AU - Choi, Sung Kyu. AU - Kweon, Young Oh. AU - Jeong, Sook Hyang. AU - Lee, Myung Seok. AU - Choi, Jong Young. AU - Kim, Dae Ghon. AU - Yun, Soo Kim. AU - Heon, Young Lee. AU - Yoo, Kwon. AU - Yoo, Hee Won. AU - Lee, Hyo Suk. PY - 2007/5. Y1 - 2007/5. N2 - Clevudine is a pyrimidine analogue with potent and sustained antiviral activity against HBV. The present study ...
2011) Viruses 3, 83-101.. Hepatitis B virus (HBV) genomes are small, semi-double-stranded DNA circular genomes that contain alternating overlapping reading frames and replicate through an RNA intermediary phase. This complex biology has presented a challenge to estimating an evolutionary rate for HBV, leading to difficulties resolving the evolutionary and epidemiological history of the virus. Here, we re-examine rates of HBV evolution using a novel data set of 112 within-host, transmission history (pedigree) and among-host genomes isolated over 20 years from the indigenous peoples of the South Pacific, combined with 248 previously published HBV genomes. We employ Bayesian phylogenetic approaches to examine several potential causes and consequences of evolutionary rate variation in HBV. Our results reveal rate variation both between genotypes and across the genome, as well as strikingly slower rates when genomes are sampled in the Hepatitis B e antigen positive state, compared to the e antigen ...
It is estimated that there are 350 million world wide carriers of the hepatitis B virus, mostly coming from Asia (Lai et al., 2005). With immigration of Chinese into Western countries, hepatitis B is now becoming established in countries where it was previously uncommon. Chronic hepatitis B infection is a prevalent disease especially in the Toronto and Vancouver areas where most Asians live. Fortunately, over the past decade effective anti-viral treatments have become available. Chronic hepatitis B is mostly an asymptomatic disease, therefore, serological and imaging tests should be used to identify, follow and treat those considered high risk ...
PubMedID: 26100697 | Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response. | Antimicrobial agents and chemotherapy | 9/1/2015
In patients with chronic hepatitis B infection, treatment with pegylated interferon has effected a fast and significant decline in hepatitis B virus RNA.
To assess the role of hepatitis B e antigen HBeAg and its interaction with hepatitis B surface antigen HBsAg on the development of hepatocellular carcinoma HCC, this case-control study included 361 age-and sex-matched pairs of patients with histologically proven HCC and healthy control subjects. HBsAg, HBeAg and antibody to HBeAg anti-HBe were...
The SR-domain protein kinase (SRPK) 1 and 2 are two important kinases, which can bind to the hepatitis B virus (HBV) core protein and may be responsible for the phosphorylation of the core protein. The HBV precore protein contains core protein sequence plus an additional 29 amino acids in the N-terminus. The HBV e antigen is formed after processing of the precore to the p22e protein. Here, the role of SRPK1 and SRPK2 in the processing of the precore was determined. SRPK1 and SRPK2 can affect the precore processing in a kinase activity dependent manner; however, they have no significant effect on HBeAg secretion. Using confocal microscopy, I show that precore protein and SRPK2 colocalized, suggesting their physical interaction. Thus, these findings indicate that SRPK1 and SRPK2 can bind and phosphorylate the precore in the cytoplasm and affect the processing of the precore without affecting the HBeAg secretion ...
In approximately 9 years after initiating NA administration, 44 % (17/39) of HBeAg-negative patients and 15 % (8/55) of HBeAg-positive patients were under control without NA. In other words, more than half of HBeAg-negative and most of HBeAg-positive patients still need NA therapy, suggesting difficulty in stopping NA therapy.. In this study we adopted the APASL stopping recommendation [12]. Most of the HBeAg-negative patients (95 %) satisfied this stopping criteria, whereas only one forth of the HBeAg-positive patients (27 %) did. These results are in agreement with a study [15] reporting that seroconversion from HBeAg-positive to HBeAb-positive occurred only in 38 % of HBeAg-positive patients through 4 year-treatment of ETV. Multivariate analysis revealed that patients with lower serum HBV-DNA levels were more likely to meet the stopping criteria in concordance with the previous study [15]. Thus, patients with higher serum HBV-DNA will have difficulty to cease NA treatment once it ...
Looking for online definition of CD49e antigen in the Medical Dictionary? CD49e antigen explanation free. What is CD49e antigen? Meaning of CD49e antigen medical term. What does CD49e antigen mean?
Aims: The aim was to test the efficacy of a pre-S2-containing vaccine (Genhevac-B) in chronic hepatitis B (CHB). Twenty-five naive patients (22 male, three female; median age 35; range: 6-69 years) with CHB were recruited. The inclusion criteria were: hepatitis B e antigen (HBeAg) positive or HBV-DNA detectable with liquid hybridization; alanine aminotransferase (ALT) is at least 1.5-fold the upper normal limit and histological evidence of chronic hepatitis. ...
To date no network meta-analysis (NMA) has accounted for baseline variations in viral load when assessing the relative efficacy of interventions for chronic hepatitis B (CHB). We undertook baseline-adjusted and unadjusted analyses using the same data to explore the impact of baseline viral load (BVL) on CHB treatment response. We searched Embase, Medline, Medline in Process and the Cochrane CENTRAL databases for randomised clinical trials (RCTs) of monotherapy interventions at licensed doses for use in CHB. Search strategies comprised CHB disease and drug terms (a combination of controlled vocabulary and free text terms) and also a bespoke RCT filter. The NMA was undertaken in WinBUGs using fixed and random effects methods, using data obtained from a systematic review. Individual patient data (IPD) from an entecavir clinical trial were used to quantify the impact of different baseline characteristics (in particular undetectable viral load (UVL) at 1 year) on relative treatment effect. Study level mean
Background. Cost and clinically significant adverse effects are the major limiting factors of interferon (IFN) use in therapy for chronic hepatitis B virus (HBV) infection. A clinical trial was conducted in China to study the efficiency and clinical relevance of low-dose regimen of IFN treatment for chronic HBV infection and to reveal factors predicting sustained combined response.. Methods. During a randomized, open-label control study, hepatitis B e antigen (HBeAg)-positive patients with chronic HBV infection (n = 230) were assigned to receive pegylated IFN-α-2b (1.0 µg/kg) (n = 115) or IFN-α-2b (3 MIU; n = 115) for a 24-week period. Sustained combined response was assessed 24 weeks after the completion of treatment.. Results. The greater rate of HBeAg loss in the pegylated IFN-group (23%) was the only statistically significant difference between the 2 treatment arms observed at the end of follow-up. The results of the multivariate statistical analysis revealed that HBV genotype B and ...
After patients completed 96 weeks of treatment and emtricitabine was stopped, patients were followed off treatment for 6 months. Treatment-free follow-up data showed continued virologic response for 19 of 69 patients (28% with HBV DNA levels ≦4700copies/mL), serologic response for 20 of 50 patients (40% seroconversion to anti-HBe), and normal ALT for 38 of 66 patients (58%). Similar relapse rates were observed for both HBeAg positive and HBeAg negative patients for both HBV DNA and ALT, i.e. HBV DNA >LOD and/or ALT abnormal at follow-up week 24 for patients with HBV DNA < LOD and/or ALT normal at week 96. Of the patients who had seroconverted to anti-HBe by week 96 (n=22), four patients reverted to HBeAg positive and one patient lost anti-HBe but remained HBeAg negative at the end of the treatment-free follow-up; the other 17 patients (77%) had stable seroconversion. Of the 78 patients with at least 1 day of follow-up, 15 patients (19%) experienced exacerbation of hepatitis. Generally, ...
Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited. In this retrospective multicenter study we therefore assessed the long-term efficacy of TDF monotherapy in patients with prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels ,4.0 log10copies/mL at the start and aminimum period of TDF therapy for at least 6 months. In all, 131 patients (mean age 42 ± 12 years, 95 male, 65% hepatitis B e antigen [HBeAg]-positive) were eligible. Pretreatment consisted of either monotherapy with lamivudine (LAM; n = 18), adefovir (ADV; n = 8), and sequential LAM-ADV therapy (n = 73), or add-on combination therapy with both drugs (n = 29). Three patients had failed entecavir therapy. Resistance analysis in 113 of the 131 patients revealed genotypic LAM and ADV resistance in 62% and 19% ...
WLL has a patient with hepatitis C that was contracted during a blood transfusion over 10 years ago. The infection was associated with a slowly increasing alanine aminotransferase (ALT) level over the past two years. Liver biopsy showed mild to moderate inflammation with no cirrhosis. WLLs patient had read about using vitamin E, 400 IU per day, to reduce levels of ALT, hepatitis B e antigen and hepatitis B e antibody in patients with hepatitis B virus (Ann Intern Med 1998;128:156-7). In addition, he had heard of using the hepatoprotective botanical milk thistle (Silybum marianum) for reducing transaminase levels in patients with chronic active hepatitis (Int J Clin Pharmacol Ther Toxicol 1993;31:456-60) and alcoholic cirrhosis (J Hepatol 1989;9:105-13). The patient wanted to try them. So, he and WLL discussed the risks (which appeared to be few according to the literature) and benefits (which were only anecdotal for treatment of hepatitis C) and decided on a trial-of-one. WLL performed a ...
Background: In chronic hepatitis B (CHB), the presence of hepatic steatosis (HS) seems to be associated with known host and viral factors which may influence the long-term prognosis of chronic hepatitis B (CHB), probably leading to cirrhosis and hepatocellular carcinoma (HCC). Different from chronic hepatitis C (CHC), factors associated with HS in CHB are not clearly explored. Materials and Methods: 160 CHB patients were divided into two groups depending on the results of liver biopsy. Group I consisted of 71 patients with confirmed steatosis. Group II comprised 89 patients without steatosis. The groups were compared in terms of basal characteristics, body mass index (BMI), liver enzymes (ALT, AST, ALP), serum fasting blood sugar (FBS) and lipids, hepatitis B e antigen (HBeAg), viral load, and histological findings. Results: In terms of host factors, male gender, older age, BMI, high serum FBS and lipid levels were associated with HS. On the other hand, ALT levels, the HAI scores of ...
Specifications HBeAg mAb2: Antibody against E Antigen of Hepatitis B Virus Catalogue # Immunogen Source Host Clone Applications MD-A28-Ab2 Mouse Monoclonal ELISA, Lateral flow immunoassay Grade Ion-exchange purified >95% Storage & Stability Store at 2-8°C. The product is stable in the unopened vial until the expiry date given. For long-term storage, freeze at -20°C. Avoid repetitive freezing and thawing. Concentration Format Specificity Recognizes e antigen of hepatitis B. Isotype IgG1 Affinity Constant Titer Hazards Intended for laboratory and manufacturing use only. Not for drug, food or household use. Standard laboratory practices should be followed when handling.
Hepatitis B virus (HBV) infections represent a global health problem, since these account for 350 million chronic infections worldwide that result in 500 000-700 000 deaths each year. Control of viral replication and HBV-related disease and mortality are of utmost importance. Because the currently available antiviral therapies all have major limitations, new strategies to treat chronic HBV infection are eagerly awaited. Six single-domain antibodies (VHHs) targeting the core antigen of HBV (HBcAg) have been generated and three of these bound strongly to HBcAg of both subtype ayw and adw. These three VHHs were studied as intrabodies directed towards the nucleus or the cytoplasm of a hepatoma cell line that was co-transfected with HBV. A speckled staining of HBcAg was observed in the cytoplasm of cells transfected with nucleotropic VHH intrabodies. Moreover, an increased intracellular accumulation of hepatitis B e antigen (HBeAg) and a complete disappearance of intracellular HBcAg signal were observed with
Adult patients (18-69 years of age) with HBeAg positive chronic hepatitis B (HBsAg positive for more than 6 months) with serum HBV DNA ,10 to the 6 copies /mL, ALT levels ,2 x ULN and less than or equal to 10x ULN and a Knodell necroinflammatory score of greater than or equal to 3 and a Knodell fibrosis score , 4. However, up to 96 patients with cirrhosis, i.e. knodell fibrosis score equal to 4, will be eligible for enrollment. Patients who have not had a bopisy within 6 months at baseline must agree to undergo a liver biopsy prior to randomisation. No evidence of hepatocellular carcinoma (HCC) ie. fetoptotein 50 ng/mL at screening. Patients are wligible if they are treatment naive, ie less than 12 weeks of prior nucleoside or nucleotide (adefovir, dipivoxil or tenofovir DF) treatment. Any previous treatment with nucleosides and nucleotides (eg up to 12 weeks) and interferon (pegylated or not) must have ended at least 6 months prior to the pre-treatment biopsy. ...
Chronic carriers of hepatitis B infection often harbour virus strains with mutations in the precore region. These mutations are temporally associated with the development of HBeAg loss and seroconversion to anti-HBe. The most common precore mutation is a stop codon at position 1896, but other mutations leading to abolished HBeAg secretion have been described. Here, a novel precore mutation introducing a lysine in the precore position 28, a sequence shared by non-human primates but not by other human isolates, is described. However, the insertion causes a frame-shift preventing the expression of HBeAg by introducing a stop codon 5 aa downstream of the mutation. Analysis of the predicted RNA secondary structure indicates that the insertion could occur without fatally affecting the stability of the stem-loop encapsidation signal.
To determine which baseline factors of chronic hepatitis B patients are predictive of virological response to Peginterferon alpha-2b therapy. A total of 21 HBeAg-positive chronic hepatitis B (CHB) patients treated with Peginterferon alpha-2b were recruited. They were treated with Peginterferon alpha-2b (0.5-1.0 microg/kg per week) for 24 wk and followed ...
Objective: To investigate the optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B (CHB) after suboptimal response to 24 weeks of pegylated interferon (Peg-IFN) α-2a. Methods: A total of 188 patients with HBeAg-positive CHB who had suboptimal response to 24 weeks of Peg-IFN α-2a were randomly divided into entecavir group (n = 93) and telbivudine group (n = 95). The two groups received entecavir 0.5 mg/d and telbivudine 0.6 g/d, respectively, for 208 weeks. After 208 weeks of treatment, the following indices were assessed: HBeAg clearance rate and seroconversion rate, hepatitis B virus (HBV) DNA clearance rate (HBV DNA , 500 IU/ml), safety, and drug resistance rate ...
52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Antiretroviral Drugs with Dual Activities against HBV and HIV. Among the ARV drugs, 3TC, FTC, TAF, and TDF all have activity against HBV. Entecavir is an HBV nucleoside analog which also has weak HIV activity. TAF is a tenofovir prodrug with HBV activity and potentially less renal and bone toxicities than TDF. The efficacy of TDF versus TAF in patients with HBV monoinfection was evaluated in a randomized controlled trial of HBV treatment-naive and treatment-experienced HBeAg-negative patients. In this study, TAF was noninferior to TDF based on the percentage of patients with HBV DNA levels ,29 IU/mL at 48 weeks of therapy (94% for TAF vs. 93% for TDF; P = .47).18 TAF was also noninferior to TDF in HBeAg-positive patients with chronic HBV monoinfection with a similar percentage of patients achieving HBV DNA levels ,29 IU/mL at 48 weeks of therapy (64% for TAF vs. 67% for TDF; P = .25).19 In both studies, patients on TAF experienced significantly smaller mean percentage decreases from baseline in ...
Determine if the E (RH3) antigen is expressed on the patients red blood cells. To determine if the patient is heterozygous or homozygous for the E antigen, Little e Antigen Typing - Patient (2007943) should also be ordered.. ...
Lamivudine was previously the only oral medication for chronic hepatitis B infection and had problems with rapid induction of viral resistance, which led to severe hepatitis flares in some affected patients. Tailoring therapy to those patients at increased risk of disease progression has been important, given the known risks of treatment. The presence or absence of hepatitis B envelope antigen (HBeAg) provides some important prognostic information. Those patients who are initially HBeAg-positive but then seroconvert to a negative antigen status with positive envelope antibody and suppressed viral load are known to have decreased progression of liver disease. In contrast, infected patients who have ongoing viral replication in the presence of negative HBeAg and positive envelope antibody appear to have more risk for severe and progressive liver injury. Marcellin and colleagues from Adefovir Study Group 437 (use of adefovir in HBeAg-positive patients) and Hadziyannis and colleagues from Adefovir ...
RESULTS: During a mean follow-up of 68 months, HBsAg loss occurred in 32 patients, including 16 (8%) of 196 untreated patients (mean annual incidence 0.8%), 8 (10%) of 82 interferon (IFN) alpha-treated patients and eight patients who had been treated with other antivirals or steroids. The 5-yr probability of HBsAg loss was 4% and 16% for untreated and IFN-treated patients, respectively (p = 0.0001). Coxs regression analysis identified hepatitis B e antigen-positivity at entry as the sole independent prognostic factor for HBsAg loss. Of the 32 patients who lost HBsAg, one (3%) subsequently developed hepatocellular carcinoma (HCC) and died, whereas, among the patients who remained HBsAg-positive, 11% developed HCC and 20% had died. The probability of HCC appearance was lower (p = 0.0137) and survival was longer (p = 0.0006) in patients who cleared HBsAg compared with patients with HBsAg persistence ...
HBeAg, the hepatitis B e-antigen, is a protein that circulates in the blood during active infection with the virus, but it may clear in recovery.
Buy 460 Sundancer Express Cruisers by Sea Ray for sale in B & E Marine Inc., Indiana from B & E Marine on BoatBuys. Verified seller, complete information. Find your deal!
Hepatitis B surface antigen. *Antibody to hepatitis C. *Antibody to HIV, usually subtypes 1 and 2 ... For example, the HIV antibody test will not detect a recently infected donor, so some blood banks use a p24 antigen or HIV ... The screening includes testing for diseases that can be transmitted by a blood transfusion, including HIV and viral hepatitis. ... and viral hepatitis. Screening may include questions about risk factors for various diseases, such as travel to countries at ...
Coleman, Paul F. (2017-02-17). "Detecting Hepatitis B Surface Antigen Mutants". Emerging Infectious Diseases. 12 (2): 198-203. ... Breakthrough cases of Hepatitis B are primarily attributed to mutations in the Hepatitis B virus (HBV) that make HBV surface ... Breakthrough infections of Hepatitis B and mumps are partially attributed to antigenic drift. Vaccines may fail to provide ... If B cell receptors bind to the antigen and FC receptors simultaneously bind to the maternal antibody, the FC receptors send a ...
Hepatitis B: certain antigens present during hepatitis can accumulate in the kidneys and damage them. ... Liver failure caused by cirrhosis, hepatitis and other conditions such as alcoholism, IV drug use or some hereditary diseases ... HIV: the virus's antigens provoke an obstruction in the glomerular capillary's lumen that alters normal kidney function. ...
In 1964, while studying "yellow jaundice" (hepatitis), he discovered a surface antigen for hepatitis B in the blood of an ... 3. The age of antigens and electronic microscopy" [History of hepatitis. 3. The age of antigens and electronic microscopy]. La ... a nonprofit organization dedicated to finding a cure for hepatitis B and improving the lives of those affected by hepatitis B ... Blumberg and his team were able to develop a screening test for the hepatitis B virus, to prevent its spread in blood donations ...
... has been found to have homology to hepatitis delta virus antigen (HDAg). DIPA interacts with the viral antigen, HDAg, and can ... Long M, de Souza SJ, Gilbert W (May 1997). "Delta-interacting protein A and the origin of hepatitis delta antigen". Science. ... Brazas R, Ganem D (Oct 1996). "A cellular homolog of hepatitis delta antigen: implications for viral replication and evolution ... Hepatitis delta virus (HDV) is a pathogenic human virus whose RNA genome and replication cycle resemble those of plant viroids ...
Alipour, Elias (23 June 2013). "Gold nanoparticle based capacitive immunosensor for detection of hepatitis B surface antigen". ... Hepatitis B Prepared AuNPs-Hepatitis B virus (HBV) DNA gene probes could be used to detect HBV DNA directly. The detection- ...
... (core antigen) is a hepatitis B viral protein. It is an indicator of active viral replication; this means the person ... May 2003). "New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg ... HBcAg is an antigen that can be found on the surface of the nucleocapsid core (the inner most layer of the hepatitis B virus). ... "In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type ...
December 1993). "Human leukocyte antigen A1-B8-DR3-DQ2-DPB1*0401 extended haplotype in autoimmune hepatitis". Hepatology. 18 (6 ... In autoimmune hepatitis[edit]. In 1972, a link between "HLA A1,8" (current:HLA A1-B8) active chronic hepatitis, subsequently B8 ... human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors". Hepatology. 13 (4): 701-6. doi:10.1002/hep.1840130415 ... "Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients". World J. Gastroenterol. 12 (34): ...
... they will bind to antigens within the HEp-2 cell nucleus. These antibodies can be visualised by subsequent incubation with anti ... Extractable nuclear antigens[edit]. Extractable nuclear antigens (ENA) are a group of autoantigens that were originally ... Typically, HEp-2 cells are used as a substrate to detect the antibodies in human serum. Microscope slides are coated with HEp-2 ... Comparison with autoimmune hepatitis and impact on the disease profile". Hepatology. 26 (3): 561-566. doi:10.1002/hep.510260305 ...
"Stimulation of RNA polymerase II elongation by hepatitis delta antigen". Science. 293 (5527): 124-7. doi:10.1126/science. ...
The coating, hepatitis B surface antigen (HBsAg), is not infectious; however, HBsAG can provoke an immune response. In order to ... Donald G. McNeil, Jr., April 26, 2012, Irving Millman Dies at 88; Worked to Stop Hepatitis B, The New York Times. His Hepatitis ... Millman's work with Baruch Blumberg helped lead to the creation of a test to detect hepatitis B. The test allowed blood banks ... Millman and Blumberg found that the blood of individuals who carried the hepatitis B virus contained particles of the outside ...
The appearance is classically associated with abundant hepatitis B antigen in the endoplasmic reticulum, but may also be drug- ... Hadziyannis, S; Gerber, MA; Vissoulis, C; Popper, H (Nov 1973). "Cytoplasmic hepatitis B antigen in "ground-glass" hepatocytes ... In the context of hepatitis B, GGHs are only seen in chronic infections, i.e. they are not seen in acute hepatitis B. GGHs were ... Drug reaction Mallory body Viral hepatitis Micrograph showing ground glass hepatocytes. H&E stain. Micrograph showing ground ...
Kumar GB, Ganapathi TR, Revathi CJ, Srinivas L, Bapat VA (October 2005). "Expression of hepatitis B surface antigen in ... Dendritic cell vaccines combine dendritic cells with antigens in order to present the antigens to the body's white blood cells ... such as the hepatitis B surface antigen). They can generate TH and antibody responses, but not killer T cell responses.[ ... This presents the antigen in such a way as to produce a greater action than the simple aqueous tetanus toxoid. People who have ...
... (also known as the Australia antigen) is the surface antigen of the hepatitis B virus (HBV). It indicates current ... Today, these antigen-proteins can be genetically manufactured (e.g. transgene E. coli) to produce material for a simple antigen ... "Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem". BMC Clinical Pathology. 12 (1): 15 ... The viral envelope of an enveloped virus has different surface proteins from the rest of the virus which act as antigens. These ...
Hepatitis Weekley, Autoimmune Diseases, "Cytotoxic Antigen Induces Hypophysitis in Cancer Patients," 2006-1-9; see also, Weston ... "Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic ...
"Fibronectin and asialoglyprotein receptor mediate hepatitis B surface antigen binding to the cell surface". Arch. Virol. 155 (6 ... The asialoglycoprotein receptor may facilitate hepatic infection by multiple viruses including hepatitis B, and is also a ... "Asialoglycoprotein receptor interacts with the preS1 domain of hepatitis B virus in vivo and in vitro". Arch. Virol. 156 (4): ...
"Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis". Lancet. 355 (9214): 1510-5. doi:10.1016/ ... "Entrez Gene: SLA/LP soluble liver antigen/liver pancreas antigen". Herkel J, Heidrich B, Nieraad N, Wies I, Rother M, Lohse AW ... Volkmann M, Martin L, Bäurle A, Heid H, Strassburg CP, Trautwein C, Fiehn W, Manns MP (2001). "Soluble liver antigen: isolation ... SECp43 and soluble liver antigen, in the selenoprotein synthesis machinery". J. Biol. Chem. 280 (50): 41568-75. doi:10.1074/jbc ...
West, D. J.; Calandra, G. B. (1996). "Vaccine induced immunologic memory for hepatitis B surface antigen: implications for ...
Yap SF (June 2004). "Hepatitis B: review of development from the discovery of the "Australia Antigen" to end of the twentieth ... Bihl F, Negro F (May 2010). "Hepatitis E virus: a zoonosis adapting to humans". The Journal of Antimicrobial Chemotherapy. 65 ( ... In 1963, the hepatitis B virus was discovered by Baruch Blumberg (b. 1925).[67] Reverse transcriptase, the key enzyme that ... Zetterström R (March 2008). "Nobel Prize to Baruch Blumberg for the discovery of the aetiology of hepatitis B". Acta ...
Hraber P, Kuiken C, Yusim K (December 2007). "Evidence for human leukocyte antigen heterozygote advantage against hepatitis C ... doi:10.1002/hep.21889. PMID 17935228. Rikowski A, Grammer K (May 1999). "Human body odour, symmetry and attractiveness". Proc. ...
2011). "Evaluation of saliva specimens as an alternative sampling method to detect hepatitis B surface antigen". J. Clin. Lab. ... Hepatitis C has also been identified using salivary detection methods. Yaari, et al., reported in 2006 that saliva testing for ... Amado LA, Villar LM, de Paula VS, Gaspar AM (March 2008). "Comparison between serum and saliva for the detection of hepatitis A ... A 2011 study demonstrated that HBV surface antigen saliva testing using ELISA had a sensitivity and specificity of 93.6% and ...
4 December 2007). "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized ... and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B". Gastroenterology. 129 (2): 528-36. ... Telbivudine impairs hepatitis B virus (HBV) DNA replication by leading to chain termination. It differs from the natural ... "FDA: Hepatitis B Drug Discontinued". MPR. 2016-10-05. Retrieved 2021-01-11. "Telbivudine". Drug Information Portal. U.S. ...
Hraber P, Kuiken C, Yusim K (December 2007). "Evidence for human leukocyte antigen heterozygote advantage against hepatitis C ... doi:10.1002/hep.21889. PMID 17935228.. *^ Rikowski A, Grammer K (May 1999). "Human body odour, symmetry and attractiveness". ... Resistance to hepatitis C virus infectionEdit. There is evidence that genetic heterozygosity in humans provides increased ...
"HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis". Digestion. 26 (4): 213-7. doi: ... HLA-DR2 (DR2) of the HLA-DR serotype system, is a broad antigen serotype that is now preferentially covered by HLA-DR15 and HLA ... Tissue Antigens. 69 Suppl 1: 228-30. doi:10.1111/j.1399-0039.2006.77311.x. PMID 17445206. Asakura H, Tsuchiya M, Aiso S, ... primary biliary cirrhosis and autoimmune hepatitis. DR2 is also found in all patients that test positive for anti-anti-Asn-RNA- ...
... there is cross-reactivity between influenza virus-specific CD8+ T cells and hepatitis C virus antigens. Cross reactivity may ... In immunology, cross-reactivity has a more narrow meaning of the reaction between an antibody and an antigen that differs from ... There can be cross-reactivity between the immune system and the antigens of two different pathogens, or between one pathogen ... For example, the tetanus toxin is a single protein macromolecular antigen but will stimulate many immune responses due to the ...
"Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum". Lancet. 1 (7659): ... In this post she worked on hepatitis, which she was able to continue from 1943 to 1947 with funding from the Medical Research ... Davidson, C. S. (1969). "Discussions of the paper by Sheila Sherlock: "The treatment of hepatitis"". Bulletin of the New York ... Eisenmenger, W. (1969). "Discussions of the paper by Sheila Sherlock: "The treatment of hepatitis"". Bulletin of the New York ...
Kumar GB, Ganapathi TR, Revathi CJ, Srinivas L, Bapat VA (October 2005). "Expression of hepatitis B surface antigen in ... Dendritic cell vaccines combine dendritic cells with antigens in order to present the antigens to the body's white blood cells ... hepatitis A, hepatitis B, polio, mumps, measles, rubella, diphtheria, pertussis, tetanus, HiB, chickenpox, rotavirus, influenza ... This presents the antigen in such a way as to produce a greater action than the simple aqueous tetanus toxoid. People who have ...
Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune ... MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proceedings of the National ... An induced rebinding model of antigen discrimination. Trends Immunol. 2014, 35 (4): 153-8. PMC 3989030. PMID 24636916. doi: ...
"Characterization of RNA-binding domains of hepatitis delta antigen". J. Gen. Virol. 74 (Pt 11): 2473-2478. PMID 8245865.. CS1 ... hepatitis G. Viri[uredi , uredi kodo]. *↑ http://lsm1.amebis.si/lsmeds/novPogoj.aspx?pPogoj=hepatitis, Slovenski medicinski e- ... Taylor JM (2006). "Hepatitis delta virus". Virology. 344 (1): 71-76. doi:10.1016/j.virol.2005.09.033. PMID 16364738.. ... Hepatitis D je oblika hepatitisa, ki ga povzroča virus hepatitisa D (VHD); le-ta za svoj razvoj potrebuje virus hepatitisa B. ...
"First Antigen Rapid Test for Ebola through Emergency Assessment and Eligible for Procurement". World Health Organization (WHO ... and viral hepatitis among others.[104] ... a rapid antigen test which gives results in 15 minutes was ...
"Chronic Hepatitis After Hepatitis E Virus Infection in a Patient With Non-Hodgkin Lymphoma Taking Rituximab" (PDF). Retrieved ... It increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen). ... Rituximab has been reported as a possible cofactor in a chronic Hepatitis E infection in a person with lymphoma. Hepatitis E ... Other severe side effects include reactivation of hepatitis B in those previously infected, progressive multifocal ...
"Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus". J. Infect. Dis. 201 (9): 1371-80. doi ... "Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and ...
... has been reported as a possible cofactor in a chronic Hepatitis E infection in a person with lymphoma. Hepatitis E ... It increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen). ... Other severe side effects include reactivation of hepatitis B in those previously infected, progressive multifocal ...
However, immunofluorescence essays provide less definitive proof of Lassa infection.[7] An ELISA test for antigen and ... ELISA antigen assays, plaque neutralization assays, and immunofluorescence essays. ...
Liver biopsy can verify inflammation and necrosis of hepatocytes and detect viral antigens. Because of the bleeding tendency of ... Mitchell misdiagnosed the disease that he observed and treated, and the disease was probably Weil's disease or hepatitis. See: ... ribavirin in reducing liver pathology in yellow fever virus infection may be similar to its activity in treatment of hepatitis ...
The immune complexes are formed by binding of antibodies to antigens in the glomerular basement membrane. The antigens may be ... Within membranous glomerulonephritis, especially in cases caused by viral hepatitis, serum C3 levels are low.[7] ... Other studies have implicated neutral endopeptidase and cationic bovine serum albumin as antigens.[4] ... "M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy". The New England Journal of Medicine ...
Hepatitis. DNA virus. HBV (B). RNA virus. CBV. HAV (A). HCV (C). HDV (D). HEV (E). HGV (G). ... A map of the genome of JC virus, indicating the position of the tumor antigen genes (red), the three capsid protein genes ( ... Further research is needed to determine the exact etiological role of T-antigen, but there seems to be a connection to the ... T-antigen, also plays a key role in viral proliferation,[11] directing the initiation of DNA replication for the virus as well ...
... is to conjugate the antigens. Conjugation is the attachment to the antigen of another substance which also generates an immune ... A more contemporary approach for "boosting" the immune response to simpler immunogenic molecules (known as antigens) ... In the future it might be possible to artificially design antibodies to fit specific antigens, then produce them in large ... response, thus amplifying the overall response and causing a more robust immune memory to the antigen. For example, a toxoid ...
... antigen - antigen presentation - antigen-presenting cell (APC) - antineoplastic - antiprotozoal - antiretroviral drugs - ... hepatitis - hepatitis C and HIV coinfection - hepatomegaly - herpes simplex virus 1 (HSV-1) - herpes simplex virus 2 (HSV-2) - ... human leukocyte antigens (HLA) - human papilloma virus (HPV) - human T cell lymphotropic virus type I (HTLV-I) - human T cell ...
These cells bind antigens presented on MHC I complex of virus-infected or tumour cells and kill them. Nearly all nucleated ... Infectious diseases - viral (AIDS, SARS, West Nile encephalitis, hepatitis, herpes, measles, others), bacterial (TB, typhoid, ... Basophils are chiefly responsible for allergic and antigen response by releasing the chemical histamine causing the dilation of ... Dendritic cells (Although these will often migrate to local lymph nodes upon ingesting antigens) ...
Family Nackednaviridae - e.g. African cichlid nackednavirus (ACNDV), formerly named African cichlid hepatitis B virus (ACHBV).[ ... Group-specific antigen (gag) proteins are major components of the viral capsid, which are about 2000-4000 copies per virion. ... "Deciphering the Origin and Evolution of Hepatitis B Viruses by Means of a Family of Non-enveloped Fish Viruses". Cell Host & ...
In 1985, the first human vaccine obtained by genetic engineering from animal cells, the vaccine against hepatitis B, was ... as an antigen, Richard F. J. Pfeiffer introduced it in the abdomen of a guinea pig already vaccinated against this disease, and ... and hepatitis B. The discovery and use of sulfonamides in treating infections was another breakthrough. Some researchers won ... and they deduced that it can play the role of antigen, that is if they could overcome the delicate moment of its injection, ...
... whether in the form of viral hepatitis (e.g. hepatitis B or hepatitis C),[22][23][24] alcoholic liver disease, or cirrhosis of ... Serum levels of carcinoembryonic antigen (CEA) and CA19-9 are often elevated, but are not sensitive or specific enough to be ... hepatitis C, hepatitis B, infection with certain liver fluke, and some congenital liver malformations.[1][3][8] However, most ... doi:10.1002/hep.20537. PMID 15690474.. *^ Holzinger F, Z'graggen K, Büchler MW (1999). "Mechanisms of biliary carcinogenesis: a ...
"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome". Science 244 (4902): 359-62. April ... Detection by Immune Electron Microscopy of a Viruslike Antigen Associated with Acute Illness". Science 182 (4116): 1026-1028. ... Feinstone, Stephen M.; Kapikian, Albert Z.; Purcell, Robert H. (1973). "Hepatitis A: ...
The alpha-3 subunit (COL4A3) of collagen IV is thought to be the antigen implicated in Goodpasture syndrome, wherein the immune ... "Serum Collagen Type IV for the Assessment of Fibrosis and Resistance to Interferon Therapy in Chronic Hepatitis C". ... IV concentrations correlate with hepatic tissue levels of collagen IV in subjects with alcoholic liver disease and hepatitis C ...
The tests are based upon the ability of an antibody to bind specifically to an antigen. The antigen (usually a protein or ... "Hepatitis C". World Health Organization. Archived from the original on 2011-07-12. Retrieved 2013-04-25.. ... Using a similar basis as described above, immunoassays can detect or measure antigens from either infectious agents or the ... This technique is the current standard for detecting viral infections such as AIDS and hepatitis. ...
Usually, a target cell line expressing a certain surface-exposed antigen is incubated with antibody specific for that antigen. ... whose membrane-surface antigens have been bound by specific antibodies.[1] It is one of the mechanisms through which antibodies ...
Alter co-discovered the Australia antigen, a key to detecting hepatitis B virus. For many investigators that would be the ... Alter and his research team demonstrated that most post-transfusion hepatitis cases were not due to hepatitis A and hepatitis B ... Alter and his research team demonstrated that most post-transfusion hepatitis cases were not due to hepatitis A and hepatitis B ... This work eventually led to the discovery of the hepatitis C virus. In 1988 the new hepatitis virus was confirmed by Alter's ...
1 - antigen. 2 - IgE antibody. 3 - FcεRI receptor. 4 - preformed mediators (histamine, proteases, chemokines, heparin). 5 - ... Other widely promoted tests such as the antigen leukocyte cellular antibody test and the food allergy profile are considered ...
Schwann cell antigen. Neuritis, paralysis. Hashimoto's thyroiditis[1]. Thyroglobulin antigen. Hypothyroidism, hard goiter, ... Target antigen. Effects. Allergic contact dermatitis[1]. Environmental chemicals, like urushiol (from poison ivy and poison oak ... Myelin antigens (e.g., myelin basic protein). Myelin destruction, inflammation. Rheumatoid arthritis[1]. Possibly collagen and/ ... CD4+ Th1 helper T cells recognize antigen in a complex with the MHC class II major histocompatibility complex on the surface of ...
... has a 10-40-fold preference for hemimethylated DNA and interacts with the proliferating cell nuclear antigen (PCNA).[51] ... The Human Epigenome Project (HEP). *The Epigenome Network of Excellence (NoE). *Canadian Epigenetics, Environment and Health ...
For development of a system to study the replication of the virus that causes hepatitis C and for use of this system to ... cells-the preeminent component of the immune system that initiates and regulates the body's response to foreign antigens.[34] ... Discovery of the virus that causes hepatitis C and the development of screening methods that reduced the risk of blood ... transfusion-associated hepatitis in the U.S. from 30% in 1970 to virtually zero in 2000.[56] ...
... the first known hepatitis with a viral etiological agent was Hepatitis A, in the picornaviridae family. Hepatis B Virus (HBV) ... surface antigens-preS1, preS2, and S, the X protein and HBeAg. The X protein is thought to be non-structural. Its function and ... Endogenous hepatitis B virus genomes have been described in crocodilian, snake and turtle genomes.[7] This suggests that these ... Hepatitis viruses have been described in fish and amphibians also.[4] This suggests that this family has co evolved with the ...
It has been suggested that absorption of trichophyton fungal antigens can give rise to immunoglobulin E (IgE) antibody ... Hepatitis C, or HIV. Davies et al. surveyed podiatrists and found that 41% of them complained of eye problems, particularly ... of the population has allergic antibodies to fungal antigens, and half of them, that is 5% of the population, would be ... of podiatry drill burrs potentially expose the healthcare worker to aerosols containing bloodborne pathogens such as Hepatitis ...
Blood is usually collected and tested for common or serious Blood-borne diseases including Hepatitis B, Hepatitis C and HIV. ... Approximately 25 of these membrane proteins carry the various blood group antigens, such as the A, B and Rh antigens, among ... Blood Groups and Red Cell Antigens *^ a b Pierigè F, Serafini S, Rossi L, Magnani M (January 2008). "Cell-based drug delivery ... Kidd antigen protein - urea transporter;. *RhAG - gas transporter, probably of carbon dioxide, defines Rh Blood Group and the ...
Immureboost presented a product at the Therapies for Viral Hepatitis Symposium to Boston Scientists. The ... In this sense V1 is similar to the first generation of commercial Hepatitis B vaccine, which contained pooled viral antigens ... Separately, three patients who were Hepatitis B antigen positive became negative after V1 therapy. In contrast, patients who ... Hepatitis is a serious and potentially life-threatening disease which may culminate in liver cancer. Hepatitis B causes 60% to ...
Hepatitis core antigen (IPR002006). Short name: Hepatitis_core Overlapping homologous superfamilies *Viral capsid core domain ... This entry represent the core antigen of the viral capsid (HBcAg) from various Hepatitis B virus (HBV), which is a major human ... The capsid is composed of a single polypeptide, HBcAg, also known as the core antigen. The capsid has a 5-helical fold, where ... This viral capsid acts as a core antigen, the major immunodominant region lying at the tips of the alpha-helical hairpins that ...
Hepatitis-associated antigen in chronic hepatitis. Br Med J 1973; 3 :49 ... Hepatitis-associated antigen in chronic hepatitis.. Br Med J 1973; 3 doi: https://doi.org/10.1136/bmj.3.5870.49-a (Published 07 ...
Reactive Hepatitis B Surface Antigen will reflex to the Hepatitis B Surface Antigen Confirmatory neutralization test for an ... Home : For health professionals : Refer a patient : Laboratory Services : Test Table : HEPATITIS B SURFACE ANTIGEN ...
Definition of hepatitis B e antigen. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and ... hepatitis B e antigen. Definition: an antigen, or group of antigens, associated with hepatitis B infection and distinct from ... the surface antigen (HBsAg) and the core antigen (HBcAg); it is associated with the viral nucleocapsid. Its presence indicates ...
HbS antigen. positive. hep e antigen.Negative.HBV DNA.Negative.I am on treatment with lumividine tab 100 mg/day for about 3 yrs ... I am diagnosed as Hep B carrier.My test reports: ... Hep B surface antigen positive. I am diagnosed as Hep B carrier ... I am diagnosed as Hep B carrier.My test reports:HbS antigen. positive. hep e antigen.Negative.HBV DNA.Negative.I am on ... hep e antigen.Negative.HBV DNA.Negative.I am on treatment with lumividine tab 100 mg/day for about 3 yrs.My ALT level & liver ...
... gene of hepatitis B surface antigen (HBsAg) using Agrobacteriummediated transformation. Four different expression... ... Agrobacterium Edible vaccine Embryogenic cells Hepatitis B surface antigen Transgenic banana Abbreviations. ADS. Adenine ... Mason HS, Lam DMK, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc Nat Acad Sci USA 89: ... Rasthali (AAB) have been transformed with the s gene of hepatitis B surface antigen (HBsAg) using Agrobacterium mediated ...
Identification and Management of Hepatitis B Surface Antigen (HBsAg)--Positive Persons. Persons with chronic hepatitis B virus ... obtain vaccination against hepatitis A if chronic liver disease is present (2). *When seeking medical or dental care, HBsAg- ... Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization ... Hepatitis B virus transmission between children in day care. Pediatr Infect Dis J 1989;8:870--5. ...
2013 Sep;58(3):881-9. doi: 10.1002/hep.26415. Epub 2013 Jul 29. Multicenter Study; Research Support, N.I.H., Extramural; ... Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection.. Ashraf S1, Nitschke K, Warshow UM ... Human leukocyte antigen (HLA) class I presents viral peptides to CD8+ T cells to permit detection of infected cells, and ... CD8+ T-cell responses to hepatitis C virus (HCV) are important in generating a successful immune response and spontaneously ...
Hepatitis b surface antigen definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation ... hepatitis b surface antigen in Medicine Expand. hepatitis B surface antigen n. Abbr. HBsAg An antigen of the small spherical ... and filamentous forms of hepatitis B antibodies that is also present on the Dane particle. ... Nearby words for hepatitis b surface antigen. * hepatitis a * hepatitis a virus ...
Hepatitis b e antigen definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look ... hepatitis b e antigen in Medicine Expand. hepatitis B e antigen n. Abbr. HBe, HBeAg A core protein antigen of the hepatitis B ...
Hepatitis B virus-specific (HBV-specific) T cells have been identified as main effector cells in HBV clearance. In contrast, B ... cells producing neutralizing antibodies against the HBV surface antigen (HBsAg) have been studied in little detail, mainly due ...
Western and dot immunoblotting analysis of viral antigens and antibodies: application to murine hepatitis virus.. Talbot PJ, ...
What is viral hepatitis antigens? Meaning of viral hepatitis antigens medical term. What does viral hepatitis antigens mean? ... Looking for online definition of viral hepatitis antigens in the Medical Dictionary? viral hepatitis antigens explanation free ... viral hepatitis antigens. vi·ral hep·a·ti·tis an·ti·gens (vīrăl hepă-tītis anti-jĕnz) Immunogenic components of hepatitis ... Viral hepatitis antigens , definition of viral hepatitis antigens by Medical dictionary https://medical-dictionary. ...
Buy our Recombinant Hepatitis A Virus Surface Antigen protein. Ab68870 is an active protein fragment produced in Escherichia ... Recombinant Hepatitis A Virus Surface Antigen protein. See all Hepatitis A Virus Surface Antigen proteins and peptides. ... Hepatitis A virus (HAV), the causative agent of type A viral hepatitis, is spread by faecal-oral contact or ingestion of ... Microbiology Organism Virus RNA Virus ssRNA positive strand virus Hepatitis A/C/E/G ...
Buy our Recombinant Hepatitis B Virus E Antigen protein. Ab91273 is an active full length protein produced in Escherichia coli ... Hepatitis B e-antigen (HBeAg) is a viral protein associated with HBV infections. Unlike the surface antigen, the e-antigen is ... When the virus goes into "hiding," the e-antigen will no longer be present in the blood. HBeAg is often used as a marker of ... of HBV that do not make e-antigen; these are especially common in the Middle East and Asia. In areas where these strains of HBV ...
B news Hepatitis B Outreach hepatitis B vaccine hepatitis C hepatitis D hepatocellular carcinoma HepB hep B Hep B Awareness Hep ... Hepatitis B Diagnosis & Monitoring, Hepatitis B Prevention, Living with Hepatitis B Youve Lost the Hepatitis B Surface Antigen ... Tag Archives: hepatitis B surface antigen. Hepatitis B Diagnosis & Monitoring, Hepatitis B Treatment ... discrimination HBV vaccine HCC HCV HDV hepatitis B Hepatitis B Hepatitis B Foundation Hepatitis B Foundation Events Hepatitis ...
PREVALENCE OF HEPATITIS B SURFACE ANTIGEN. The rate of positive results for hepatitis B surface antigen was 0.7% in our ... All blood samples positive for hepatitis B surface antigen were also tested for hepatitis B e antigen and its antibody (Abbott ... Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in ... Of the 705 women positive for hepatitis B surface antigen, 118 (16.7%) were positive for the e antigen. The rate of positive ...
Most patients do not turn their surface antigen to negative on treatment. The next best results we hope... ... The length of treatment will depend on your type of hepatitis B infection - e antigen negative or e antigen positive. Discuss ... Ask the Experts > Forum on Hepatitis and HIV Coinfection > Q & A Antigen positive to Non-reactive. Sep 25, 2005 How long is the ... Most patients do not turn their surface antigen to negative on treatment. The next best results we hope for is to turn the ...
... then the surface antigen can mean a chronic carrier state that is inactive due to no virus in her blood. Yes I would agree that ... If your wife is at risk for hepatitis B, ... hep B Surface Antigen Positive. Feb 4, 2006 My wife recently ... If your wife is at risk for hepatitis B, then the surface antigen can mean a chronic carrier state that is inactive due to no ... Yes I would agree that she should see a specialist to be certain that: 1. The hepatitis B surface antigen was confirmed. 2. To ...
"Australia antigen", later renamed HBsAg (for hepatitis B surface antigen), in patient blood [6]. HBeAg (hepatitis B e antigen) ... Milich D, Liang J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003 ;38 ... Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J. Virol. 1989 ;63:798-808 ... Mutation preventing formation of the hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989 ;2:588- ...
This invention relates to a DNA fragment comprising a base sequence encoding a non-A non-B hepatitis-specific antigen ... Non-A non-B hepatitis specific antigen and its use in hepatitis ... hepatitis B, hepatitis D and other hepatitis symptoms caused by ... with serum from a normal person or non-A non-B hepatitis patient, wherein the antigens used are a purified antigen in A, an ... 1. An isolated DNA fragment coding for a non-A non-B hepatitis-specific antigen polyopeptide, said DNA fragment having a ...
Browse our Hepatitis C Virus Core Antigen all backed by our Guarantee+. ... Hepatitis C Virus Core Antigen available through Novus Biologicals. ...
Browse our Hepatitis A Surface Antigen Antibody catalog backed by our Guarantee+. ... Hepatitis A Surface Antigen Antibodies available through Novus Biologicals. ... Hepatitis A Surface Antigen Antibodies. We offer Hepatitis A Surface Antigen Antibodies for use in common research applications ... Choose from our Hepatitis A Surface Antigen monoclonal antibodies.. Alternate Names for Hepatitis A Surface Antigen Antibodies ...
LBDHBG - Hepatitis B surface antigen. Variable Name: LBDHBG SAS Label: Hepatitis B surface antigen. English Text: Hepatitis B ... LBDHD - Hepatitis D (anti-HDV). Variable Name: LBDHD SAS Label: Hepatitis D (anti-HDV). English Text: Hepatitis D (anti-HDV). ... Hepatitis B: Core Antibody, Surface Antigen; Hepatitis D Antibody (HEPBD_G) Data File: HEPBD_G.xpt First Published: September ... The Hepatitis B surface antigen is tested only when the Hepatitis B core antibody test is positive. Participant results are ...
LBDHBG - Hepatitis B surface antigen. Variable Name: LBDHBG. SAS Label: Hepatitis B surface antigen. English Text: Hepatitis B ... Hepatitis B: Core Antibody, Surface Antigen; Hepatitis D Antibody (HEPBD_D) Data File: HEPBD_D.xpt First Published: February ... LBDHD - Hepatitis D (anti-HDV). Variable Name: LBDHD. SAS Label: Hepatitis D (anti-HDV). English Text: Hepatitis D (anti-HDV). ... LBXHBC - Hepatitis B core antibody. Variable Name: LBXHBC. SAS Label: Hepatitis B core antibody. English Text: Hepatitis B core ...
Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria  Egah, D.Z.; Banwat, E.B. ... Prevalence of hepatitis B surface antigen and hepatitis C virus antibodies among blood donors in Alexandria, Egypt  Wasfi, O.A ... Serum level of anti-hepatitis B surface antigen 6-8 years after hepatitis B vaccination at birth  Kazemi, A.; Koosha, A.; ... were tested for hepatitis B surface antigen [‎HBsAg]‎ and anti-hepatitis C virus [‎HCV]‎ antibodies. A total of 119 donors [‎ ...
History of Hepatitis B; Detection of antigen in serum of acute hepatitis; Comments on delta agent of the antigen. ... Association of the discovery of the Australia antigen or hepatitis-associated antigen with... ... Hepatitis-Associated Antigen and Viruses. London, W. Thomas // Annals of Internal Medicine;Apr73, Vol. 78 Issue 4, p624 Reviews ... Familial hepatoma with hepatitis-associated antigen. Denison, Edward K.; Peters, Robert L.; Reynolds, Telfer B.; Denison, E K; ...
Different guidelines exist for the management of hepatitis B virus (HBV)-infected healthcare workers (HCWs). Various HBV DNA ... Different guidelines exist for the management of hepatitis B virus (HBV)-infected healthcare workers (HCWs). Various HBV DNA ... Hepatitis B e antigen-positive Healthcare Workers More in this Section.... Infection Prevention and Safety Issue TOOLKITS. ...
Hepatitis B Virus Core Antigen Antibody (13A9), MA1-7606, from Invitrogen™. Species Reactivity: Virus; Applications: ELISA, ... The antigens in the outer surface are called as hepatitis B virus surface antigens. Core antigens are localized within the ... Antibodies to surface antigens appear in circulation at an early stage of infection whereas the antibodies to the core antigens ... The antigenic activity of the nucleocapsid core is designated as hepatitis B core antigen. ...
  • Rasthali (AAB) have been transformed with the ' s ' gene of hepatitis B surface antigen (HBsAg) using Agrobacterium mediated transformation. (springer.com)
  • In contrast, B cells producing neutralizing antibodies against the HBV surface antigen (HBsAg) have been studied in little detail, mainly due to methodical limitations. (jci.org)
  • HBsAg, the protein that makes up the surface of the virus, is what labs look for in a blood sample to determine if a person is currently infected with hepatitis B. (hepb.org)
  • The strange thing about HBsAg, is that each hepatitis B virus requires only about 100 HBsAg molecules to provide its envelope protein, but the virus produces about 100- to 1 million-times more HBsAg than is needed, leaving millions of HBsAg circulating in the bloodstream," explained Timothy Block, president of the Hepatitis B Foundation and the Baruch S. Blumberg Institute, the foundation's research arm. (hepb.org)
  • Bottom line: A low or undetectable HBsAg level means patients are winning the war against hepatitis B and their risk of liver damage is greatly reduced. (hepb.org)
  • According to Quest Diagnostics, which created the test, measuring HBsAg levels better identifies which patients are at risk of hepatitis B reactivation. (hepb.org)
  • The virus was first discovered as "Australia antigen", later renamed HBsAg (for hepatitis B surface antigen), in patient blood [ 6 ]. (medsci.org)
  • Hepatitis B patients also contain circulating antibodies against HBcAg (hepatitis B core antigen), and will develop antibodies against HBeAg and HBsAg (anti-HBe and anti-HBs) at later stages of infection. (medsci.org)
  • We determined the serum level of antibody to hepatitis B surface antigen [‎anti-HBsAg]‎ in 273 randomly selected 7-9-year-old schoolchildren from Zanjan City, Islamic Republic of Iran, who had been fully vaccinated against hepatitis B starting at birth. (who.int)
  • The 55 codons upstream of the gene sequence encoding the hepatitis B surface antigen (HBsAg) are called the pre-S(2) region. (sciencemag.org)
  • Hepatitis D virus (HDV) is an incomplete RNA virus that needs hepatitis B surface antigen (HBsAg) to help its replication. (clinicaltrials.gov)
  • To estimate the prevalence of hepatitis D virus infection among HBsAg positive individuals. (clinicaltrials.gov)
  • Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. (curehunter.com)
  • Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. (curehunter.com)
  • Mutations that occur within the immunodominant epitopes of hepatitis B surface antigen (HBsAg) allow mutant virus to propagate in the presence of a neutralizing immune response, while wild-type virus is reduced to undetectable levels. (cdc.gov)
  • An understanding of immunoassay reactivity with HBsAg mutants is key to establishing an appropriate testing algorithm for hepatitis B virus detection programs. (cdc.gov)
  • This article addresses recent information concerning the emergence of hepatitis B surface antigen (HBsAg) mutants, their impact on viral antigen presentation, latest prevalence data, and discussion of the issues associated with detection of mutants in healthcare settings. (cdc.gov)
  • Treatment with a combination of tenofovir and pegylated interferon yielded higher rates of hepatitis B surface antigen (HBsAg) loss than when either drug was used singly. (hcplive.com)
  • A documented past history of hepatitis, living in 'asocial' wards in which at least one HBsAg carrier was present, long institutionalization (is greater than 10 yrs.), admission to the institution between ages 5 and 19, a present age between 20 and 39, and being male were associated with the presence of anti-HBs. (arctichealth.org)
  • 112 (34%) were females, 258 (79%) were injecting drug users (IDU), 25 (8%) were men who have sex with men (MSM), and 20 (6%) were hepatitis B surface antigen (HBsAg)-positive. (arctichealth.org)
  • The occurrence of the delta (delta) agent was analyzed in 89 patients with acute hepatitis B infection during 1976-1979 in Gothenburg, Sweden, and in 46 patients (16 drug addicts) with chronic HBsAg-positive liver disease. (arctichealth.org)
  • HBsAg is the surface antigenof the Hepatitis-B-Virus (HBV). (prospecbio.com)
  • HBsAg is a serological marker produced on the surface of the hepatitis B virus and is one of the first disease state markers to be detected in the serum of patients infected with the hepatitis B virus. (prospecbio.com)
  • Pregnant women are screened for a different antigen, the hepatitis B surface antigen (HBsAg) that also show an active infection with hepatitis B. If that test is positive, the HBeAg test may be done, along with tests such as the HBV DNA concentration and alanine aminotransferase (ALT) test for liver health. (verywell.com)
  • In hepatitis B, it's common to test for the hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg). (verywell.com)
  • This guidance provides recommendations for a requalification method or process for the reentry of deferred donors who test repeatedly reactive for hepatitis B surface antigen (HBsAg), confirmed positive by neutralization, following a recent vaccination against hepatitis B virus (HBV) infection, and who are not infected by HBV. (fda.gov)
  • To explore the predictive value of serum hepatitis B surface antigen (HBsAg) titer and transient elastography in screening for insignificant fibrosis in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. (dovepress.com)
  • We assessed the serum HBsAg level, serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level, HBV genotypes, liver stiffness measurement (LSM) values by transient elastography, and histological fibrosis staging by METAVIR classification. (dovepress.com)
  • Hepatitis B virus surface antigen (HBsAg) is an important risk factor for hepatocellular carcinoma (HCC) and is downregulated during hepatocarcinogenesis. (sigmaaldrich.com)
  • An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. (arctichealth.org)
  • Hepatitis B Virus Surface antigen (HBsAg) standard, for use in running standard curves in AlphaLISA assays. (perkinelmer.com)
  • A total of 69 persons were investigated for assessment of cell-mediated and humoral immunity to hepatitis B surface antigen (HBsAg). (asm.org)
  • Three groups, each consisting of 20 normal persons, 20HBsAg carriers, and 20 convalescent hepatitis B patients, were studied for HBsAg, anti-HBs, and leukocyte migration inhibition with purified HBsAg. (asm.org)
  • Sequential sampling if an additional group of nine acute hepatitis B patients defined the cellular and humoral immune response to HBsAg. (asm.org)
  • The antigen was eliminated rapidly by mounting of cell-mediated immune response detectable for a limited period, followed by antibody response in relatively few patients moore than 3 months after clearance of circulating HBsAg. (asm.org)
  • Thirty-five cases with hepatitis B surface antigen (HBsAg) positivity known prior to initiation of TNF-α inhibitors were identified. (springer.com)
  • While such reactivation may be due to a variety of reasons, clinicians prescribing TNF-α inhibitors to HBsAg-positive patients should consider prophylactic antiviral therapy and close monitoring for any clinical or serological evidence of hepatitis. (springer.com)
  • The age-specific prevalence of hepatitis B surface antigen (HBsAg) and antibody was studied in a random sample of Gilbert and Ellice islanders over the age of 10 years living in Nauru. (ajtmh.org)
  • The original term for the Australian antigen, now called hepatitis B surface antigen (HBsAg). (thefreedictionary.com)
  • Percentage of HBsAg-positive subjects detected using the hepatitis sAg/eAg test versus the HBsAg standard provided by NIBSC. (asm.org)
  • For comparing factors between AHB patients with viral persistence and those with self-limited infection, 212 AHB patients without human immunodeficiency virus (HIV) coinfection were observed in 38 liver centers until serum hepatitis B surface antigen (HBsAg) disappeared or a minimum of 6 months in cases where HBsAg persisted. (sigmaaldrich.com)
  • Many cell types efficiently present an epitope of the hepatitis B surface Ag (HBsAg) to murine class I-restricted CTL following an in vitro pulse with native 22-nm HBsAg particles. (jimmunol.org)
  • We have analyzed the molecular bases of the persistence of hepatitis B virus (HBV) DNA in serum and peripheral blood mononuclear cells (PBMC) in the absence of detectable hepatitis B surface antigen (HBsAg) in hemodialysis patients and dialysis-unit staff members who had suffered acute hepatitis B that resolved previously. (nih.gov)
  • No serum HBsAg/hepatitis B surface antigen antibody (anti-HBs) immune complexes or mutations in the "a determinant of the S gene were found. (nih.gov)
  • HBsAg serum level (quantification) may be useful for managing hepatitis B virus (HBV) infection patients. (scirp.org)
  • The objective of this study was to estimate the correlation between HBsAg serum level and liver fibrosis severity with treatment naive chronic hepatitis B patients in Cote d'Ivoire. (scirp.org)
  • Conclusion: This study shows that there's a negative correlation between HBsAg serum level and liver fibrosis severity treatment naive with African chronic hepatitis B viral HBeAg-negative patients. (scirp.org)
  • The hepatitis virus consists of a core containing DNA ( HBV-DNA ) with an enzyme known as DNA polymerase that assists with viral replication and is surrounded by surface proteins ( HBsAg ). (healthhype.com)
  • The surface proteins surrounding the viral core is known as the hepatitis B surface antigen ( HBsAg ). (healthhype.com)
  • Home » Products » Health Beauty » Diagnosis Equipment » HBsAg Test Strip/Hepatitis B Surface Antigen Test In total 213268 number ofProductsinfo,Released today. (dahmw.org)
  • This entry represent the core antigen of the viral capsid (HBcAg) from various Hepatitis B virus (HBV), which is a major human pathogen. (ebi.ac.uk)
  • The capsid is composed of a single polypeptide, HBcAg, also known as the core antigen. (ebi.ac.uk)
  • Molecular cloning and sequencing of the HBV genome led to the redefinition of the three HBV antigens as viral gene products endowed with specific functions in viral life cycle [for an in-depth review on the molecular biology of HBV, see ref. 13].The HBcAg and HBeAg are alternative translation products of the core gene, with HBeAg translation requiring an upstream precore region ATG codon (Fig. 2 ). (medsci.org)
  • This involves the reaction of anti-HBc in the sample with hepatitis B core antigen (HBcAg) coated wells. (cdc.gov)
  • Several assays have been developed for the measurement of serum hepatitis B e antigen (HBeAg) or hepatitis B core antigen (HBcAg) concentrations ( 1 , 3 , 16 ). (asm.org)
  • Since HBeAg and HBcAg share a 149-amino-acid sequence identity, they are collectively called hepatitis B core-related antigens (HBcrAg) ( 5 , 13 ). (asm.org)
  • In this assay, the specimens were pretreated so that HBeAg and HBcAg were released from the patients' own anti-HBe and anti-HBc antibody-antigen complexes, respectively. (asm.org)
  • Hepatitis B e-antigen (HBeAg) is a viral protein associated with HBV infections. (abcam.com)
  • successful treatment will usually eliminate HBeAg from the blood and lead to development of antibodies against e-antigen (anti-HBe). (abcam.com)
  • The core promoter mutants express less HBe antigen (HBeAg) through transcriptional down regulation, while precore mutants express truncated products. (medsci.org)
  • HBeAg (hepatitis B e antigen) was identified several years later as a marker for patients at high risk for transmission of the disease [ 20 ]. (medsci.org)
  • Hepatitis B e antigen positive (HBeAg-positive) children are at high risk of severe complications such as hepatocellular carcinoma and cirrhosis. (hindawi.com)
  • By revisiting our previous screen of microRNA plasma levels in HBeAg-positive and HBeAg-negative children with chronic hepatitis B (CHB) and in healthy controls, candidate microRNAs with aberrant plasma expressions in HBeAg-positive children were identified. (hindawi.com)
  • Risk of progressive liver disease primarily applies to hepatitis B e antigen positive (HBeAg-positive) children and seroclearance of HBeAg is a key event in the natural course of disease [ 5 ]. (hindawi.com)
  • HBeAg stands for hepatitis B e-antigen . (verywell.com)
  • People with chronic hepatitis B can show seroconversion-the levels of HBeAg dropping until they're undetectable while levels of anti-HBe antibodies develop. (verywell.com)
  • Interestingly, there are strains of hepatitis B virus that don't produce HBeAg. (verywell.com)
  • They can have an active Hepatitis B infection without a positive HBeAg test . (verywell.com)
  • Liaw Y-F. HBeAg Seroconversion as an Important End Point in the Treatment of Chronic Hepatitis B. Hepatology International . (verywell.com)
  • The proliferative response of PBMC to hepatitis B virus (HBV) envelope, core, and e Ag was analyzed prospectively in 21 patients with acute self-limited HBV infection and compared with the response of patients with chronic HBV infection and different levels of HBV replication (i.e., hepatitis e Ag (HBeAg)- or anti-HBe-positive) and liver damage (i.e., chronic active hepatitis or chronic asymptomatic carriers). (jimmunol.org)
  • Percentage of HBeAg-positive subjects detected using the hepatitis sAg/eAg test versus the PEI HBeAg standard. (asm.org)
  • The objectives of this review were to assess the effects of the sequential combination of glucocorticosteroids and interferon compared to interferon alone in the treatment of chronic hepatitis B. Glucocorticosteroid pretreatment was associated with a significantly higher frequency of loss of hepatitis B markers (HBeAg and HBV DNA), but had no significant effect on clinical outcomes. (cochrane.org)
  • Mellerup MT, Krogsgaard K, Mathurin P, Gluud C, Poynard T. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database of Systematic Reviews 2005, Issue 3. (cochrane.org)
  • In this sense V1 is similar to the first generation of commercial Hepatitis B vaccine, which contained pooled viral antigens derived from the blood of hepatitis B carriers. (prweb.com)
  • Western and dot immunoblotting analysis of viral antigens and antibodies: application to murine hepatitis virus. (nih.gov)
  • This assay detected picogram quantities of viral antigens and antibodies. (nih.gov)
  • And B-cells, so they don't generate the antibodies needed to destroy the viral antigens that make up the virus. (hepb.org)
  • Two-step immunohistochemical staining showed the expression of viral antigens in situ. (unboundmedicine.com)
  • Trans Am Clin Climatol Assoc. 2019;130:104-118 Authors: Alter HJ Abstract The modern age of viral hepatitis began in the early 1960s with the serendipitous discovery of the Australia antigen, a protein that was later shown to represent the envelope of the hepatitis B virus leading to its designation as the hepatitis B surface antigen. (medworm.com)
  • Authors: Mak LY, Ko KL, To WP, Wong DK, Seto WK, Fung J, Yuen MF Abstract Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. (medworm.com)
  • Unvaccinated sex partners and household and needle-sharing contacts should be tested for susceptibility to HBV infection (see Appendix A, Prevaccination Serologic Testing for Susceptibility) and should receive the first dose of hepatitis B vaccine immediately after collection of blood for serologic testing. (cdc.gov)
  • Since the availability of hepatitis B vaccine the prevention of perinatal transmission of hepatitis B virus has become feasible. (bmj.com)
  • Duration of Immunity After Hepatitis B Vaccination: Efficacy of Low-Dose Booster Vaccine. (ebscohost.com)
  • Studies health care workers three years after initial vaccination with hepatitis B vaccine to determine the prevalence of immunity indicated by levels of antibody to hepatitis B surface antigen. (ebscohost.com)
  • Decline of vaccine coverage for hepatitis B. (ebscohost.com)
  • A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. (arctichealth.org)
  • In 1991, the World at least 6-8 years before with 3 doses of Health Organization (WHO) recommended hepatitis B vaccine starting at birth to that hepatitis B vaccination be included provide information on the effect of the in national immunization programmes in immunization strategy for hepatitis B and countries with a hepatitis B surface antigen the need for booster doses. (who.int)
  • This was the first marker for any hepatitis virus and became not only a diagnostic assay, but also a mandatory blood donor screening test and the basis for the first generation hepatitis B vaccine. (medworm.com)
  • Hepatitis B vaccine is effective in preventing infection with hepatitis B virus (HBV), but its duration of protection is unknown. (ovid.com)
  • Breakthrough cases of Hepatitis B are primarily attributed to mutations in the Hepatitis B virus (HBV) that make HBV surface proteins unrecognizable to antibodies produced from the HBV vaccine. (wikipedia.org)
  • A boost in antibody to hepatitis B surface antigen (anti-HBs) was defined as a fourfold rise in levels to ≥20 mIU/mL that was not accompanied by the presence of antibody to hepatitis B core antigen or attributable to interim vaccination. (ovid.com)
  • A core protein antigen of the hepatitis B virus distinct from both the surface and core antigens. (dictionary.com)
  • Hepatitis delta virus (HDV) is known to express a protein termed the small delta antigen, a structural protein which is also essential for genome replication. (asm.org)
  • The antigen is a protein that binds specifically on one of these surface proteins. (prospecbio.com)
  • This antigen is a protein from the hepatitis B virus that circulates in infected blood when the virus is actively replicating. (verywell.com)
  • An antigen is a protein that stimulates an immune system response, causing your body to produce antibodies to fight invaders. (verywell.com)
  • Three of the children had antibodies to hepatitis B core protein. (who.int)
  • Hepatitis delta antigen (HDAg) is a nuclear protein that is intimately involved in hepatitis delta virus (HDV) RNA replication. (pubmedcentralcanada.ca)
  • The viral genomic RNA (G-RNA) is first replicated into the full-length antigenomic RNA (AG-RNA) and is also transcribed into a 0.8-kb mRNA, which encodes the only HDV protein, hepatitis delta antigen (HDAg). (pubmedcentralcanada.ca)
  • Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. (curehunter.com)
  • Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. (medworm.com)
  • Hepatitis B Surface Antigen Serum Level Is Correlated with Fibrosis Severity in Treatment-Naïve, Chronic Hepatitis B Patients in Côte d'Ivoire (West Africa)? (scirp.org)
  • This paper describes six mother and infant pairs where the mother developed serum hepatitis during pregnancy. (bmj.com)
  • Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. (sigmaaldrich.com)
  • Association of the discovery of the Australia antigen or hepatitis-associated antigen with. (ebscohost.com)
  • The Immureboost Company presented poster 'Normalization of Elevated Liver Enzymes due to V-1 Immureboost Therapy' at the international symposium Therapies for Viral Hepatitis held in Boston on October 29-31, 2002. (prweb.com)
  • Hepatitis is a serious and potentially life-threatening disease which may culminate in liver cancer. (prweb.com)
  • Hepatitis B causes 60% to 80% of the world's primary liver cancer with over one million people dying annually. (prweb.com)
  • Diagnosis of virally induced chronic hepatitis is often made when a patient presents elevated liver enzyme levels known as alanine (ALT or SGPT) and aspartate (AST or SGOT) aminotransferases. (prweb.com)
  • hep e antigen.Negative.HBV DNA.Negative.I am on treatment with lumividine tab 100 mg/day for about 3 yrs.My ALT level & liver ultrasound test normal.I wish to go abroad for a job and there Hep.B Surface antigen is tested.If one is positive, it is a sure rejection.Can inj. (medhelp.org)
  • Persons with chronic hepatitis B virus (HBV) infection are at high risk for chronic liver disease and are a major reservoir of HBV infection. (cdc.gov)
  • The core promoter mutants have been associated with the development of fulminant hepatitis during acute infection and liver cancer during chronic infection. (medsci.org)
  • Investigation of SEN Virus Infection in Patients with Cryptogenic Acute Liver Failure, Hepatitis-Associated Aplastic Anemia, or Acute and Chronic Non--A--E Hepatitis. (ebscohost.com)
  • The hepatitis-associated liver injury in HIV-infected cases has been one of the important reasons for mortality and morbidity in. (ebscohost.com)
  • The article discusses the increasing threats of Hepatitis B Virus (HBV), which attacks the liver cells and leads to cirrhosis, liver failure and liver cancer. (ebscohost.com)
  • Exacerbation of chronic liver disease due to hepatitis B surface antigen after delta infection. (ebscohost.com)
  • The hepatitis B virus is an important cause of acute and chronic liver disease. (fishersci.com)
  • In conclusion, serum HBcrAg levels correlated with HBV virological markers and reflected the chronic hepatitis B disease activity in the liver. (asm.org)
  • Jörg Petersen, MD, PhD, Director of the Liver Institute at IFI Institute for Interdisciplinary Medicine, University of Hamburg, presented findings from an international multicenter study of chronic hepatitis B (CHB) patients during The Liver Meeting 2014 in Boston, MA. (hcplive.com)
  • Antibodies to hepatitis C virus, hepatitis B serology and liver enzymes were examined in 137 Finnish haemophiliac patients to detect signs of chronic viral hepatitis and its possible aetiological associations. (arctichealth.org)
  • Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. (umassmed.edu)
  • Chronic hepatitis C is a serious liver disease that often results in cirrhosis or hepatocellular carcinoma. (mdpi.com)
  • N-glycopeptide signatures of IgA2 in serum from patients with hepatitis B virus-related liver diseases. (medworm.com)
  • Autoimmune hepatitis (AIH) can arise de novo after liver transplantation (LT) for non-autoimmune liver diseases. (medsci.org)
  • The objectives were to assess the effects of the sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone in hepatitis B 'e' antigen positive chronic hepatitis B on mortality, virological response, biochemical response, liver histology, quality of life, and adverse events. (cochrane.org)
  • Proceedings: Serial liver biopsies in hepatitis B antigen carriers. (bmj.com)
  • Hepatitis is the term for inflammation of the liver and may be due to infectious or non-infectious causes. (healthhype.com)
  • The five types of hepatitis viruses are common infectious causes of liver inflammation, and some like hepatitis A (HAV), B (HBV) and C (HCV) are more frequently seen infectious agents. (healthhype.com)
  • The hepatitis B virus (HBV) can infect the liver cells resulting in an acute infection or persist with chronic inflammation of the liver. (healthhype.com)
  • Fulminant hepatitis with destruction of large parts of the liver is life-threatening. (healthhype.com)
  • In chronic hepatitis B infection, the patient may be asymptomatic for long periods of time until there is severe damage to the liver. (healthhype.com)
  • Chronic hepatitis B is seen where the virus does not clear and the infection persists past 6 months.The clinical features of chronic HBV infection depends on the degree of liver damage. (healthhype.com)
  • A carrier is a person with chronic hepatitis B showing no symptoms of the infection and there is no damage to the liver. (healthhype.com)
  • Worldwide, over 300 million persons are chronically infected with hepatitis B virus (HBV), which can cause chronic liver disease and hepatocellular carcinoma ( 22 , 35 ). (asm.org)
  • Hep G2 (or HepG2) is a human liver cancer cell line. (wikipedia.org)
  • Hep G2 is an immortal cell line which was derived in 1975 from the liver tissue of a 15-year-old Caucasian male from Argentina with a well-differentiated hepatocellular carcinoma. (wikipedia.org)
  • citation needed] Hep G2 cells and their derivatives are also used as a model system for studies of liver metabolism and toxicity of xenobiotics, the detection of environmental and dietary cytotoxic and genotoxic (and thus cytoprotective, anti-genotoxic, and cogenotoxic) agents, understanding hepatocarcinogenesis[citation needed], and for drug targeting studies[citation needed]. (wikipedia.org)
  • Hep G2 cells are also employed in trials with bio-artificial liver devices[citation needed]. (wikipedia.org)
  • 8%). During delivery of recommended hepatitis B vaccination services (e.g. (cdc.gov)
  • The duration of protection after hepatitis B vaccination in children is unknown. (who.int)
  • Integration of hepatitis B vaccination into rural African primary health care programmes. (ebscohost.com)
  • Examines the integration of hepatitis B vaccination into rural health care programs in South Africa. (ebscohost.com)
  • The primary aim of the study is to show that the antibody response to hepatitis B, acellular pertussis toxin and inactivated poliovirus antigens after the 4th vaccination with Hexavac® is not influenced by the concomitant administration of NeisVac-C. (clinicaltrials.gov)
  • It has been reported that when hepatitis services is good throughout the territory, B vaccination is initiated at birth, there and vaccinations are delivered through local is an increased likelihood that the child health districts which are able to reach the will complete the series [ 8,9 ] hence an whole population. (who.int)
  • In this review, hepatitis B virus (HBV) and HCC prevalence, distribution and prevalence of different genotypes, and male/female infection frequencies in relation to the vaccination status in the Mediterranean countries were reported. (medworm.com)
  • Interferon is an established treatment for chronic infection with hepatitis B virus. (cochrane.org)
  • The recombinant polypeptide and the single strand DNA sequence for PCR primer make it possible to detect the non-A non-B hepatitis virus with extremely high accuracy. (freepatentsonline.com)
  • Recombinant hepatitis B surface antigen of ayw subtype. (genetex.com)
  • A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. (curehunter.com)
  • High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. (curehunter.com)
  • Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. (curehunter.com)
  • Human leukocyte antigen (HLA) class I presents viral peptides to CD8+ T cells to permit detection of infected cells, and tapasin is an important component of the peptide loading complex for HLA class I. We sought to determine if tapasin polymorphisms affected the outcome of HCV infection. (nih.gov)
  • Detection of antibodies to HIV-1 gp41- and HLA class II antigen-derived peptides in SLE patients. (biomedsearch.com)
  • A sensitive chemiluminescence enzyme immunoassay has been developed for hepatitis B virus (HBV) core-related antigen (HBcrAg) detection. (asm.org)
  • HCV Core antigen is suitbale for ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems. (prospecbio.com)
  • No absolute correlation between the detection of HBs Ag, or previous history of hepatitis, jaundice, or current hepatitis was found. (bmj.com)
  • The Hunan Jynda ELISA had the lowest sensitivity (59.5%), and the authors concluded that ELISA assays are probably a less reliable technology for HCV antigen detection than assays which use signal amplification that allows enhancement of antigen detection. (hivandhepatitis.com)
  • HCV core-antigen can be used as a marker of viraemia as there is good non-linear correlation with HCV-RNA (r=0.87 vs. Abbot Real-Time qRT-PCR) with the lower limit of detection corresponding to HCV viral load of 700-1100 IU/ml [10]. (natap.org)
  • Co-infection with hepatitis D virus (HDV) in persons with acute or chronic hepatitis B virus (HBV) infection can lead to fulminant hepatitis. (cdc.gov)
  • About 20% to 30% of coinfections of HDV and HBV in humans develop fatal fulminant hepatitis versus 2% of patients with acute hepatitis B mono-infection. (clinicaltrials.gov)
  • Hepatitis delta virus (HDV) causes chronic and, occasionally, fulminant hepatitis in humans ( 16 ). (pubmedcentralcanada.ca)
  • To develop a low cost, high compliance screening programme for identification of carriers of hepatitis B surface antigen in the obstetric population of the Netherlands. (bmj.com)
  • Globally, about 248 million people are chronic HBV surface antigen carriers, and about 5% of them also had hepatitis delta virus (HDV) infection as well. (clinicaltrials.gov)
  • Twenty-five (13.3%) of the 188 individuals who were studied became chronic carriers of hepatitis B surface antigen. (arctichealth.org)
  • Among patients who were four years of age or less when infected, 28.8% became chronic carriers of hepatitis B, as compared with 7.7% of those who were 30 years of age or older. (arctichealth.org)
  • The literature is also reviewed and it is concluded that neonatal hepatitis seldom occurs in infants whose mothers have hepatitis early in pregnancy or are chronic carriers of Australia antigen. (bmj.com)
  • The prevalence of infection for at least 15 years, that antibody hepatitis B carriers varies in different parts levels decrease the most among persons of the world, ranging from less than 1% to immunized at 4 years of age or younger, and 15% [ 2 ]. (who.int)
  • In the Islamic Republic of Iran the level have been exposed to HBV and about 3% of antibodies to hepatitis B in vaccinated are chronic carriers, ranging from 1.7% individuals is not known. (who.int)
  • HDV is a satellite virus which requires hepatitis B virus (HBV) to supply envelope proteins for virus assembly and production ( 46 ). (pubmedcentralcanada.ca)
  • Viral proteins (antigens) trigger the immune system to produce corresponding antibodies. (healthhype.com)
  • Because of their high degree of morphological and functional differentiation in vitro, Hep G2 cells are a suitable model to study the intracellular trafficking and dynamics of bile canalicular, sinusoidal membrane proteins, and lipids in human hepatocytes in vitro. (wikipedia.org)
  • HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. (curehunter.com)
  • In this retrospective study, we investigated the prevalence and significance of mutations in part of the hepatitis B virus (HBV) x gene, and tried to clarify their relationship with clinicopathological or histopathological characteristics and prognosis in patients with chronic hepatitis B (CHB). (unboundmedicine.com)
  • We hypothesized that single-nucleotide polymorphisms (SNPs) in the gene encoding CTLA-4 may affect the vigor of the T-cell response to hepatitis B virus (HBV) infection, thus influencing viral persistence. (asm.org)
  • The expression levels of the antigen in the plants grown under in vitro conditions as well as the green house hardened plants were estimated by ELISA for all the four constructs. (springer.com)
  • We offer Hepatitis A Surface Antigen Antibodies for use in common research applications: ELISA, Radioimmunoassay. (novusbio.com)
  • ELISA procedures provide a means for routinely detecting antibodies to specific antigens. (cdc.gov)
  • The International Immunodiagnostics HDV Ab assay is a competitive enzyme immunoassay (ELISA) for the determination of antibodies to Hepatitis D Virus or HDV in human plasma and sera with a 'two step" methodology. (cdc.gov)
  • Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection. (nih.gov)
  • Hepatitis B virus (HBV) chronically infects 300 million people worldwide, and increases their risk to develop hepatocellular carcinoma by a hundred fold [ 3 ]. (medsci.org)
  • Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. (ebscohost.com)
  • Describes the prevalence of hepatitis-associated antigen (HAA) in patients with primary hepatocellular carcinoma in Taiwan. (ebscohost.com)
  • Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. (ebscohost.com)
  • This feature of the e antigen provides an assay system for laboratory diagnosis of potential clinical usefulness and suggests its possible role in pathogenesis of hepatocellular injury. (sciencemag.org)
  • Children with chronic hepatitis B (CHB) have a lifetime risk of developing hepatocellular carcinoma (HCC) up to 25% and an incidence of cirrhosis of 2-3% per year [ 1 , 2 ]. (hindawi.com)
  • Worldwide, hepatitis B infection is one of the main causes of hepatocellular carcinoma and cirrhosis. (ebscohost.com)
  • A Systematic Review of the Current Hepatitis B Viral Infection and Hepatocellular Carcinoma Situation in Mediterranean Countries. (medworm.com)
  • Sera from 521 residents of an institution for the mentally retarded near Helsinki, Finland were examined by a hemagglutination assay to determine the distribution and titers of antibodies to hepatitis B surface antigen (anti-HBs). (arctichealth.org)
  • This viral capsid acts as a core antigen, the major immunodominant region lying at the tips of the alpha-helical hairpins that form spikes on the capsid surface. (ebi.ac.uk)
  • It contains the Hepatitis B Virus HBe adw immunodominant region. (abcam.com)
  • Rapid antigen processing and presentation of a protective and immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell epitope. (doaj.org)
  • To better define the immunological mechanisms underlying HLA-B*27-mediated protection in HCV infection, we analyzed the functional avidity, functional profile, antiviral efficacy and naïve precursor frequency of CD8+ T cells targeting the immunodominant HLA-B*27-restricted HCV-specific epitope as well as its antigen processing and presentation. (doaj.org)
  • Our data suggest that rapid antigen processing may be a key immunological feature of this protective and immunodominant HLA-B*27-restricted HCV-specific epitope. (doaj.org)
  • The review, published in Annals of Internal Medicine on 20 June, compared the sensitivity and specificity of five commercially available tests for hepatitis C core antigen compared to nucleic acid testing for HCV RNA. (aidsmap.com)
  • In this study HCV core-antigen testing on the Architect platform displayed high sensitivity (100%) and specificity (97.96%) in diagnosing acute HCV in HIV-infected individuals who experience elevated transaminases. (natap.org)
  • New immunization strategies have been developed to eliminate the spread of HBV and hepatitis A virus (HAV) in the United States. (cdc.gov)
  • Immunization against hepatitis B is an important component of preventative medicine and is offered to all children in approximately 30 countries. (fishersci.com)
  • A Cross-Sectional Study of Anti-Hepatitis B Antibody Status in STD Patients: Need for Improved Immunization. (ebscohost.com)
  • Elimination of New Chronic Hepatitis B Virus Infections: Results of the Alaska Immunization Program. (ebscohost.com)
  • Evaluates the effectiveness of a hepatitis B immunization program in eliminating hepatitis B virus (HBV) transmission among Alaska Natives in a region in which HBV is endemic. (ebscohost.com)
  • Practices (ACIP), is the introduction of study carried out from February 2003 to hepatitis B immunization at birth [ 5,6 ]. (who.int)
  • Testing for hepatitis C virus core antigen could eventually replace the current two-step procedure for diagnosing chronic hepatitis C infection in lower- and middle-income countries, speeding up access to treatment and improving retention in care, a systematic review designed to inform World Health Organization hepatitis C testing guidelines has found. (aidsmap.com)
  • Testing for hepatitis C virus (HCV) core antigen could eventually replace the current 2-step procedure for diagnosing chronic hepatitis C infection in lower- and middle-income countries, speeding up access to treatment and improving retention in care, a systematic review designed to inform World Health Organization hepatitis C testing guidelines has found. (hivandhepatitis.com)
  • The systematic review was not able to assess the performance of HCV antigen assays across different HCV genotypes or in HIV/HCV coinfected people due to lack of data. (hivandhepatitis.com)
  • Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. (hivandhepatitis.com)
  • I am diagnosed as Hep B carrier.My test reports:HbS antigen. (medhelp.org)
  • If your wife is at risk for hepatitis B , then the surface antigen can mean a chronic carrier state that is inactive due to no virus in her blood. (thebody.com)
  • Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. (arctichealth.org)
  • These findings are compared with those in three Australian antigen carrier mothers and their babies. (bmj.com)
  • A person with hepatitis B can be asymptomatic for long periods of time but may still be a carrier and spread the virus among different contacts. (healthhype.com)
  • CD8+ T-cell responses to hepatitis C virus (HCV) are important in generating a successful immune response and spontaneously clearing infection. (nih.gov)
  • Hepatitis B viral mutants can emerge in patients as a result of selection pressure from either immune response or treatment options. (cdc.gov)
  • Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. (jimmunol.org)
  • Replication of the hepatitis B virion is, therefore, the sole requirement for generating these nucleotide mismatch sequences. (cdc.gov)
  • During replication, posttranscriptional RNA editing specifically modifies some of the HDV RNA, leading to the production of an elongated form of the delta antigen, the large form, which is essential for virus assembly. (asm.org)
  • Prospective serological surveys of 1,280 seronegative Yupik Eskimos, performed between 1971 and 1976, identified 189 (14.8%) who developed serological evidence of hepatitis B virus infection. (arctichealth.org)
  • About 500 million individuals worldwide are infected with two major types of hepatitis B and C viruses. (prweb.com)
  • Thus, it is possible that V-1 Immureboost might be useful for treating hepatitis, especially when one considers the fact that immunogenic constituents of V1 are derived from HIV-infected donors many of whom are co-infected with hepatitis B and C viruses. (prweb.com)
  • Immunogenic components of hepatitis viruses. (thefreedictionary.com)
  • Unlike the surface antigen, the e-antigen is found in the blood only when there are viruses also present. (abcam.com)
  • Hepatitis viruses constitute a major public health problem because of the morbidity and mortality associated with the acute and chronic consequences of these infections. (cdc.gov)
  • In addition, NHANES provides the means to better define the epidemiology of other hepatitis viruses. (cdc.gov)
  • NHANES testing for markers of infection with hepatitis viruses will be used to determine secular trends in infection rates across most age and racial/ethnic groups, and will provide a national picture of the epidemiologic determinants of these infections. (cdc.gov)
  • Hepatitis-Associated Antigen and Viruses. (ebscohost.com)
  • Reviews the book 'Hepatitis-Associated Antigen and Viruses,' by A. J. Zuckerman. (ebscohost.com)
  • A cross-sectional study evaluated the prevalence of and the risk factors for hepatitis C and B viruses among 700 adults above the age of 40 years in a rural area of South Korea. (ebscohost.com)
  • INTRODUCTION Co-infections between hepatitis B and HIV viruses are frequent due to their similar epidemiological characteristics. (ebscohost.com)
  • Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving Rituximab. (ebscohost.com)
  • A letter to the editor on acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was having rituximab therapy is presented. (ebscohost.com)
  • The proportion of patients who progress to chronicity following acute hepatitis B (AHB) varies widely worldwide. (sigmaaldrich.com)
  • Acute hepatitis with subsequent recovery and total clearance of the virus in a person with a healthy immune system. (healthhype.com)
  • Acute hepatitis B lasts for less than 6 months. (healthhype.com)
  • Pregnant women who are positive for hepatitis B surface antigen should be identified before delivery to prevent hepatitis B infection in their neonates by passive or active immunisation, or both. (bmj.com)
  • Other clinical markers aiding the hepatitis diagnosis are abnormal levels of alkaline phosphatase and bilirubin. (prweb.com)
  • Over the past decade, the importance of hepatitis B virus (HBV) mutants has made a transition from an academic phenomenon of unknown prevalence to a factor for consideration during disease diagnosis. (cdc.gov)
  • The two-step diagnostic process is seen as a major obstacle to diagnosis and treatment of hepatitis C on the scale needed to achieve ambitious targets for reducing the burden of the disease and eliminating hepatitis C as a public health problem. (aidsmap.com)
  • A rapid point-of-care test for HCV antigen that could be used by health care workers in the same way as point-of-care tests for HIV or HCV antibodies was viewed as the highest priority for improving HCV diagnosis, and a feasible target for product development, by a recent stakeholder consultation convened by the Forum for Collaborative HIV Research and the Foundation for Innovative Diagnostics (FIND). (aidsmap.com)
  • HCV RNA tests can cost between $13 and $100 per test, and the cost of diagnosis and monitoring may increase the overall cost of curing hepatitis C by one-third in some settings. (aidsmap.com)
  • In this study we compare the utility of HCV core-antigen compared to qRT-PCR in the diagnosis on acute HCV in an HIV-positive cohort. (natap.org)
  • In Upper Egypt, data about the prevalence, clinical, laboratory and virological characters of Hepatitis D virus-infected patients is rare. (clinicaltrials.gov)
  • Twenty-six (13.8%) developed clinical hepatitis during the interval when seroconversion occurred. (arctichealth.org)
  • The clinical significance of persistently normal ALT in chronic hepatitis B infection. (umassmed.edu)
  • These observations suggest that the male homosexual population represents a pool of individuals within which the hepatitis B virus is readily transmitted, mainly as a subclinical infection although clinical hepatitis does occur in some patients. (bmj.com)
  • Pretreatment with glucocorticosteroids before treatment with alfa interferon in patients with hepatitis B 'e' antigen positive chronic hepatitis B may be more effective than treatment with alfa interferon alone with regard to loss of hepatitis B 'e' antigen and hepatitis B virus DNA, but evidence for effect on clinical outcomes is lacking. (cochrane.org)
  • Randomised clinical trials comparing identical alfa interferon treatment regimens with and without glucocorticosteroid pretreatment for hepatitis B 'e' antigen positive chronic hepatitis. (cochrane.org)
  • Can be used to detect antibodies to HIV, p24 antigen or other substances. (aidsmap.com)
  • Yamagiwa S, Kamimura H, Takamura M, Genda T, Ichida T, Nomoto M, Aoyagi Y. Presence of Antibodies against Self Human Leukocyte Antigen Class II Molecules in Autoimmune Hepatitis. (medsci.org)
  • Higher monoclonal antibody binding of 67.87% of the antigen was observed when it was expressed with a C-terminal ER retention signal. (springer.com)
  • Hepatitis B Virus X antigen Monoclonal antibody specifically detects Hepatitis B Virus X antigen in Virus samples. (fishersci.com)
  • The following antibody was used in this experiment: Hepatitis B Virus Core Antigen Monoclonal Antibody (H6F5) from Thermo Fisher Scientific, catalog # MA1-21697, RRID AB_559401. (thermofisher.com)
  • 1 2 3 Therefore, a multicentre study was designed in 1982 to determine whether efficient organisation of screening for hepatitis B could be set up in and outside hospital by adding tests for hepatitis B surface antigen to the already accepted and widely used protocol for routine antenatal screening at 14 weeks of gestation. (bmj.com)
  • Tapasin along with the transporter associated with antigen processing (TAP), ERp57 and calreticulin form the peptide loading complex (PLC), which loads viral peptides onto HLA class I. Tapasin binds to HLA class I and is thought to assist in the dissociation of peptides which bind with low affinity. (nih.gov)